

612054

## CONVENTION APPLICATION FOR A PATENT

(1) Here  
insert (in  
full) Name  
or Names of  
Applicant or  
Applicants,  
followed by  
Address (es).

XX<sub>1</sub> HOECHST AKTIENGESellschaft

(1)  
of 50 Bruningstrasse, D-6230 Frankfurt/Main 80,  
Federal Republic of Germany

(2) Here  
insert Title  
of Invention.

hereby apply for the grant of a Patent for an invention entitled: (2)  
PEPTIDES HAVING BRADYKININ ANTAGONIST ACTION

(3) Here insert  
number(s)  
of basic  
application(s)

which is described in the accompanying complete specification. This application is a  
Convention application and is based on the application numbered (3)  
P38 39 581.9, P39 16 291.5 and P39 18 225.8

(4) Here insert  
Name of basic  
Country or  
Countries, and  
basic date or  
dates

for a patent or similar protection made in (4) Federal Republic of Germany  
on 24th November 1988, 19th May 1989 and 3rd June 1989

My  
Our

Watermark Patent & Trademark Attorneys  
address for service is Messrs. Edwd. Waters & Sons, Patent Attorneys,  
50 Queen Street, Melbourne, Victoria, Australia.

DATED this 8th day of August 89

(5) Signa-  
ture (s) of  
Applicant (s)  
or  
Seal of  
Company and  
Signatures of  
its Officers as  
prescribed by  
its Articles of  
Association.

(5)

HOECHST AKTIENGESellschaft

by

D. B. Mischlewski

Registered Patent Attorney

To:

THE COMMISSIONER OF PATENTS.

COMMONWEALTH OF AUSTRALIA - Patents Act 1952

DECLARATION IN SUPPORT OF A CONVENTION APPLICATION UNDER PART XVI., FOR A PATENT

In support of the Convention application made under Part XVI. of the Patents Act 1952 by  
HOECHST AKTIENGESELLSCHAFT D-6230 Frankfurt am Main 80, Federal Republic of Germany

for a patent for an invention entitled:

Peptides having a bradykinin antagonist action

I/We, Ulrich Tergau, Am Dornbusch 3, D-6239 Eppstein/Taunus ( Fed.Rep.of Germany  
Franz Lapice, Sandweg 2, D-6233 Kelkheim (Taunus)

do solemnly and sincerely declare as follows:

1. We are authorized by HOECHST AKTIENGESELLSCHAFT  
the applicant/s for the patent to make this declaration on its/their behalf.

.. 2. The basic application/s as defined by Section 141 of the Act was/were made  
by HOECHST AKTIENGESELLSCHAFT

Federal Republic of Germany P 38 39 581.9 of November 24,1988

P 39 16 291.5 of May 19,1989

P 39 18 225.8 of June 3,1989

3.

- 1) Stephan HENKE, Wingertstraße 2c, D-6238 Hofheim am Taunus
  - 2) Hristo ANAGNOSTOPOULOS, Feldbergstraße 6, D-6204 Taunusstein
  - 3) Gerhard BREIPOHL, Geisenheimer Straße 95, D-6000 Frankfurt am Main
  - 4) Jochen KNOLLE, Höchster Straße 21, D-6239 Kriftel
  - 5) Jens STECHL, Loreleistraße 7, D-6230 Frankfurt am Main
  - 6) Bernward SCHÖLKENS, Hölderlinstraße 62, D-6233 Kelkheim (Taunus)
  - 7) Hans-Wolfram FEHLHABER, Thomas-Mann-Straße 5a, D-6270 Idstein
- 1)-7) Fed.Rep.of Germany

is/are the actual inventor/s of the invention and the facts upon which

HOECHST AKTIENGESELLSCHAFT

is/are entitled to make the application are as follows:

The said HOECHST AKTIENGESELLSCHAFT

is/are the assignee/s of the said inventor/s

4. The basic application/s referred to in paragraph 2 of this Declaration was/were the  
the first application/s made in a Convention country in respect of the invention the  
subject of the application.

Dated Frankfurt am Main, den 19.3.1990

HOECHST AKTIENGESELLSCHAFT


*U. Tergau*  
ppa. Tergau

*F. Lapice*  
i.V. Lapice

To the Commissioner of Patents

(12) PATENT ABRIDGMENT (11) Document No. AU-B-39431/89  
(19) AUSTRALIAN PATENT OFFICE (10) Acceptance No. 612054

- (54) Title  
PEPTIDES HAVING BRADYKININ ANTAGONIST ACTION
- (51)\* International Patent Classification(s)  
C07K 007/06 A61K 037/02 C07K 007/18
- (21) Application No. : 39431/89 (22) Application Date : 09.08.89
- (30) Priority Data
- (31) Number (32) Date (33) Country  
3839581 24.11.88 DE FEDERAL REPUBLIC OF GERMANY  
3916291 19.05.89 DE FEDERAL REPUBLIC OF GERMANY  
3918225 03.06.89 DE FEDERAL REPUBLIC OF GERMANY
- (43) Publication Date : 31.05.90
- (44) Publication Date of Accepted Application : 27.06.91
- (71) Applicant(s)  
HOECHST AKTIENGESSELLSCHAFT
- (72) Inventor(s)  
STEPHAN HENKE; HIRISTO ANAGNOSTOPOULOS; GERHARD BREIPOHL; JOCHEN KNOLLE; JENS STECHL; BERNWARD SCHOLKENS
- (74) Attorney or Agent  
WATERMARK PATENT & TRADEMARK ATTORNEYS, Locked Bag 5, HAWTHORN VIC 3122
- (56) Prior Art Documents  
EP 31741  
DE 3227055  
EP 52870
- (57) Claim
1. A peptide of the formula I



(I),

in which

A a<sub>1</sub>) denotes hydrogen,  
(C<sub>1</sub>-C<sub>8</sub>)-alkyl,  
(C<sub>1</sub>-C<sub>8</sub>)-alkanoyl,  
(C<sub>1</sub>-C<sub>8</sub>)-alkoxycarbonyl or  
(C<sub>1</sub>-C<sub>8</sub>)-alkylsulfonyl,

in which in each case 1, 2 or 3 hydrogen atoms are optionally replaced by 1, 2 or 3 identical or different radicals from the series comprising

carboxyl,  
amino,  
(C<sub>1</sub>-C<sub>4</sub>)-alkyl,  
(C<sub>1</sub>-C<sub>4</sub>)-alkylamino,  
hydroxyl,  
(C<sub>1</sub>-C<sub>4</sub>)-alkoxy,  
halogen,  
di-(C<sub>1</sub>-C<sub>4</sub>)-alkylamino,

(11) AU-B-39431/89  
(10) 612054

-2- Page

carbamoyl,  
sulfamoyl,  
(C<sub>1</sub>-C<sub>4</sub>)-alkoxycarbonyl,  
(C<sub>6</sub>-C<sub>12</sub>)-aryl and  
(C<sub>6</sub>-C<sub>12</sub>)-aryl-(C<sub>1</sub>-C<sub>3</sub>)-alkyl, or in which in each case  
1 hydrogen atom is optionally replaced by a radical from  
the series comprising

(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl,  
(C<sub>1</sub>-C<sub>4</sub>)-alkylsulfonyl,  
(C<sub>1</sub>-C<sub>4</sub>)-alkylsulfinyl,  
(C<sub>6</sub>-C<sub>12</sub>)-aryl-(C<sub>1</sub>-C<sub>4</sub>)-alkylsulfonyl,  
(C<sub>6</sub>-C<sub>12</sub>)-aryl-(C<sub>1</sub>-C<sub>4</sub>)-alkylsulfinyl,  
(C<sub>6</sub>-C<sub>12</sub>)-aryloxy,  
(C<sub>3</sub>-C<sub>9</sub>)-heteroaryl and  
(C<sub>3</sub>-C<sub>9</sub>)-heteroaryloxy

and

1 or 2 hydrogen atoms are replaced by 1 or 2 identical  
or different radicals from the series comprising

carboxyl,  
amino,  
(C<sub>1</sub>-C<sub>4</sub>)-alkylamino,  
hydroxyl,  
(C<sub>1</sub>-C<sub>4</sub>)-alkoxy,  
halogen,  
di-(C<sub>1</sub>-C<sub>4</sub>)-alkylamino,  
carbamoyl,  
sulfamoyl,  
(C<sub>1</sub>-C<sub>4</sub>)-alkoxycarbonyl,  
(C<sub>6</sub>-C<sub>12</sub>)-aryl and  
(C<sub>6</sub>-C<sub>12</sub>)-aryl-(C<sub>1</sub>-C<sub>3</sub>)-alkyl,

a<sub>2</sub>) denotes (C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl,  
carbamoyl, which may be optionally substituted on  
the nitrogen by (C<sub>1</sub>-C<sub>4</sub>)-alkyl or (C<sub>6</sub>-C<sub>12</sub>)-aryl,  
(C<sub>6</sub>-C<sub>12</sub>)-aryl,  
(C<sub>7</sub>-C<sub>18</sub>)-aryloyl,  
(C<sub>6</sub>-C<sub>12</sub>)-arylsulfonyl or  
(C<sub>3</sub>-C<sub>9</sub>)-heteroaryl or (C<sub>3</sub>-C<sub>9</sub>)-heteroaryloyl,  
where in the radicals defined under a<sub>1</sub>) and a<sub>2</sub>) in each


(11) AU-B-39431/89  
(10) 612054

-3-

case heteroaryl, aryloyl, arylsulfonyl and heteroaryloyl is optionally substituted by 1, 2, 3 or 4 identical or different radicals from the series comprising

carboxyl,  
amino,  
nitro,  
(C<sub>1</sub>-C<sub>6</sub>)-alkylamino,  
hydroxyl,  
(C<sub>1</sub>-C<sub>6</sub>)-alkyl,  
(C<sub>1</sub>-C<sub>6</sub>)-alkoxy,  
halogen,  
cyano,  
di-(C<sub>1</sub>-C<sub>6</sub>)-alkylamino,  
carbamoyl,  
sulfamoyl and  
(C<sub>1</sub>-C<sub>6</sub>)-alkoxycarbonyl, or

a<sub>1</sub>) denotes a radical of the formula II



R<sup>1</sup> is defined as A under a<sub>1</sub>) or a<sub>2</sub>),  
R<sup>2</sup> denotes hydrogen or methyl,  
R<sup>3</sup> denotes hydrogen or  
(C<sub>1</sub>-C<sub>6</sub>)-alkyl, preferably (C<sub>1</sub>-C<sub>4</sub>)-alkyl,  
which is optionally monosubstituted by  
amino,  
substituted amino,  
hydroxyl,  
carboxyl,  
carbamoyl,  
guanidino,  
substituted guanidino,  
ureido,  
mercapto,  
methylmercapto,  
phenyl,  
4-chlorophenyl,  
4-fluorophenyl,

(11) AU-B-39431/89  
(10) 612054

-4-

4-nitrophenyl,  
4-methoxyphenyl,  
4-hydroxyphenyl,  
phthalimido,  
4-imidazolyl,  
3-indolyl,  
2-thienyl,  
3-thienyl,  
2-pyridyl,  
3-pyridyl or  
cyclohexyl,

where substituted amino stands for a compound -NH-A- and substituted guanidino stands for a compound -NH-C(NH)-NH-A, in which A is defined as under a<sub>1</sub>) or a<sub>2</sub>); B stands for a basic amino acid in the L- or D-configuration, which may be substituted in the side chain;  
C stands for a compound of the formula IIIa or IIIb

G'-G'-Gly  
(IIIa)

G'-NH-(CH<sub>2</sub>)<sub>n</sub>-CO  
(IIIb)

in which

G' independently of one another denotes a radical of the formula IV



in which

R<sup>4</sup> and R<sup>5</sup> together with the atoms carrying them form a heterocyclic mono-, bi- or tricyclic ring system having 2 to 15 carbon atoms, and n is 2 to 8;


E stands for the radical of an aromatic amino acid;

F independently of one another denotes the radical of a neutral, acidic or basic, aliphatic or aromatic amino acid which may be substituted in the side chain, or stands for a direct bond;

(D)-Tic denotes the radical of the formula V

(11) AU-B-39431/89  
(10) 612054

-5-



(V)

- G is as defined above for G' or denotes a direct bond;  
F' is as defined for F, denotes a radical  $\text{-NH-(CH}_2\text{)}_n\text{-}$ ,  
with  $n = 2$  to  $8$ , or, if G does not denote a direct  
bond, can stand for a direct bond, and  
I is  $\text{-OH}$ ,  $\text{-NH}_2$  or  $\text{-NHC}_2\text{H}_5$ ,  
K denotes the radical  $\text{-NH-(CH}_2\text{)}_x\text{-CO-}$  with  $x = 1-4$  or  
stands for a direct bond, and  
M is as defined for F,  
and their physiologically tolerable salts.

COMMONWEALTH OF AUSTRALIA  
PATENTS ACT 1952-69

Form 10

COMPLETE SPECIFICATION  
(ORIGINAL)

612054

Class

Int. Class

Application Number:  
Lodged:

Complete Specification Lodged:

Accepted:

Published:

.....

Priority:

.....

Related Art:

.....

Name of Applicant: HOECHST AKTIENGESELLSCHAFT

.....

Address of Applicant: 50 Bruningstrasse, D-6230 Frankfurt/Main 80,  
Federal Republic of Germany

.....

Actual Inventor: STEPHEN HENKE, HIRISTO ANAGNOSTOPULOS, GERHARD BREIPOHL, JOCHEN KNOLLE  
JENS STECHL and BERNWARD SCHOLKENS

.....

Address for Service: ~~EDWARD WATERS & SONS~~ Watermark Patent & Trademark Attorneys  
50 QUEEN STREET, MELBOURNE, AUSTRALIA, 3000.

Complete Specification for the invention entitled:

PEPTIDES HAVING BRADYKININ ANTAGONIST ACTION

The following statement is a full description of this invention, including the best method of performing it known to Us



## Description

## Peptides having bradykinin antagonist action

5 The invention relates to novel peptides having bradykinin antagonist action and to a process for their preparation.

10 Bradykinin antagonist peptides are described in WO 86/07263 in which, inter alia, L-Pro in position 7 of the peptide hormone bradykinin or other bradykinin analogs is replaced by a D-amino acid, such as D-Phe, D-Thi, D-Pal, CDF, D-Nal, MDY, D-Phg, D-His, D-Trp, D-Tyr, D-hPhe, D-Val, D-Ala, D-His, D-Ile, D-Leu and DOMT.

15 The invention is based on the object of finding novel active peptides having bradykinin antagonist action.

20 This object is achieved by the peptides of the formula I  
A-B-C-E-F-K-(D)-Tic-G-M-F'-I (I),

25 in which

30 A a<sub>1</sub>) denotes hydrogen,  
(C<sub>1</sub>-C<sub>8</sub>)-alkyl,  
(C<sub>1</sub>-C<sub>8</sub>)-alkanoyl,  
(C<sub>1</sub>-C<sub>8</sub>)-alkoxycarbonyl or  
(C<sub>1</sub>-C<sub>8</sub>)-alkylsulfonyl,

35 in which in each case 1, 2 or 3 hydrogen atoms are optionally replaced by 1, 2 or 3 identical or different radicals from the series comprising

40 carboxyl,  
amino,  
(C<sub>1</sub>-C<sub>4</sub>)-alkyl,  
(C<sub>1</sub>-C<sub>4</sub>)-alkylamino,  
30 hydroxyl,  
(C<sub>1</sub>-C<sub>4</sub>)-alkoxy,  
halogen,  
di-(C<sub>1</sub>-C<sub>4</sub>)-alkylamino,

carbamoyl,  
sulfamoyl,  
(C<sub>1</sub>-C<sub>4</sub>)-alkoxycarbonyl,  
(C<sub>6</sub>-C<sub>12</sub>)-aryl and  
(C<sub>6</sub>-C<sub>12</sub>)-aryl-(C<sub>1</sub>-C<sub>3</sub>)-alkyl, or in which in each case  
1 hydrogen atom is optionally replaced by a radical from  
the series comprising

(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl,  
(C<sub>1</sub>-C<sub>4</sub>)-alkylsulfonyl,  
(C<sub>1</sub>-C<sub>4</sub>)-alkylsulfinyl,  
(C<sub>6</sub>-C<sub>12</sub>)-aryl-(C<sub>1</sub>-C<sub>4</sub>)-alkylsulfonyl,  
(C<sub>6</sub>-C<sub>12</sub>)-aryl-(C<sub>1</sub>-C<sub>4</sub>)-alkylsulfinyl,  
(C<sub>6</sub>-C<sub>12</sub>)-aryloxy,  
(C<sub>3</sub>-C<sub>9</sub>)-heteroaryl and  
(C<sub>3</sub>-C<sub>9</sub>)-heteroaryloxy

and

1 or 2 hydrogen atoms are replaced by 1 or 2 identical or different radicals from the series comprising

carboxyl,  
amino,  
(C<sub>1</sub>-C<sub>4</sub>)-alkylamino,  
hydroxyl,  
(C<sub>1</sub>-C<sub>4</sub>)-alkoxy,  
halogen,  
di-(C<sub>1</sub>-C<sub>4</sub>)-alkylamino,  
carbamoyl,  
sulfamoyl,  
(C<sub>1</sub>-C<sub>4</sub>)-alkoxycarbonyl,  
(C<sub>6</sub>-C<sub>12</sub>)-aryl and  
(C<sub>6</sub>-C<sub>12</sub>)-aryl-(C<sub>1</sub>-C<sub>3</sub>)-alkyl,

a<sub>2</sub>) denotes (C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl,  
carbamoyl, which may be optionally substituted on  
the nitrogen by (C<sub>1</sub>-C<sub>6</sub>)-alkyl or (C<sub>6</sub>-C<sub>12</sub>)-aryl,  
(C<sub>6</sub>-C<sub>12</sub>)-aryl,  
(C<sub>7</sub>-C<sub>13</sub>)-aryloyl,  
(C<sub>6</sub>-C<sub>12</sub>)-arylsulfonyl,  
(C<sub>3</sub>-C<sub>6</sub>)-heteroaryl, or (C<sub>1</sub>-C<sub>6</sub>)-heteroaryloyl,  
where in the radicals defined under a<sub>1</sub>) and a<sub>2</sub>) in each  
case aryl, heteroaryl, aryloyl, arylsulfonyl and

heteroaryloyl is optionally substituted by 1, 2, 3 or 4 identical or different radicals from the series comprising

- carboxyl,
  - 5 amino,
  - nitro,
  - (C<sub>1</sub>-C<sub>4</sub>)-alkylamino,
  - hydroxyl,
  - (C<sub>1</sub>-C<sub>4</sub>)-alkyl,
  - 10 (C<sub>1</sub>-C<sub>4</sub>)-alkoxy,
  - halogen,
  - cyano,
  - di-(C<sub>1</sub>-C<sub>4</sub>)-alkylamino,
  - carbamoyl,
  - 15 sulfamoyl and
  - (C<sub>1</sub>-C<sub>4</sub>)-alkoxycarbonyl, or
- a<sub>3</sub>) denotes a radical of the formula II
- $$\begin{array}{c} R^1 - N - CH - C - \\ | \quad | \quad || \\ R^2 \quad R^3 \quad O \end{array} \quad (II)$$
- R<sup>1</sup> is defined as A under a<sub>1</sub>) or a<sub>2</sub>),
  - 20 R<sup>2</sup> denotes hydrogen or methyl,
  - R<sup>3</sup> denotes hydrogen or
  - (C<sub>1</sub>-C<sub>6</sub>)-alkyl, preferably (C<sub>1</sub>-C<sub>4</sub>)-alkyl,
  - which is optionally monosubstituted by
  - amino,
  - 25 substituted amino,
  - hydroxyl,
  - carboxyl,
  - carbamoyl,
  - guanidino,
  - 30 substituted guanidino,
  - ureido,
  - mercapto,
  - methylmercapto,
  - phenyl,
  - 35 4-chlorophenyl,
  - 4-fluorophenyl,
  - 4-nitrophenyl,
  - 4-methoxyphenyl,

4-hydroxyphenyl,  
phthalimido,  
4-imidazolyl,  
3-indolyl,  
2-thienyl,  
3-thienyl,  
2-pyridyl,  
3-pyridyl or  
cyclohexyl,

5

10

where substituted amino stands for a compound -NH-A- and substituted guanidino stands for a compound -NH-C(NH)-NH-A, in which A is defined as under a<sub>1</sub>) or a<sub>2</sub>);

B stands for a basic amino acid in the L- or D-configuration, which may be substituted in the side chain;


C stands for a compound of the formula IIIa or IIIb

G'-G'-Gly  
(IIIa)

G'-NH-(CH<sub>2</sub>)<sub>n</sub>-CO  
(IIIb)

in which

G' independently of one another denotes a radical of the formula IV



in which

R<sup>4</sup> and R<sup>5</sup> together with the atoms carrying them form a heterocyclic mono-, bi- or tricyclic ring system having 2 to 15 carbon atoms, and


n is 2 to 8;

E stands for the radical of an aromatic amino acid;

F independently of one another denotes the radical of a neutral, acidic or basic, aliphatic or aromatic amino acid which may be substituted in the side chain, or stands for a direct bond;

30

(D)-Tic denotes the radical of the formula V



(V)

G is as defined above for G' or denotes a direct bond;

F' is as defined for F, denotes a radical  $-\text{NH}-(\text{CH}_2)_n-$ , with  $n = 2$  to  $8$ , or, if G does not denote a direct bond, can stand for a direct bond, and

I is  $-\text{OH}$ ,  $-\text{NH}_2$  or  $-\text{NHC}_2\text{H}_5$ ,

5 K denotes the radical  $-\text{NH}-(\text{CH}_2)_x-\text{CO}-$  with  $x = 1-4$  or stands for a direct bond, and

M is as defined for F,

and their physiologically tolerable salts.

10 If not stated otherwise, the abbreviation of an amino acid radical without a stereodescriptor stands for the radical in the L-form (compare Schröder, Lübke; The Peptides, Volume I, New York 1965, pages XXII-XXIII; Houben-Weyl, Methoden der Organischen Chemie (Methods of Organic Chemistry), Volume XV/1 and 2, Stuttgart 1974), such as, for example,

Aad, Abu,  $\gamma$ Abu, ABz, 2ABz,  $\epsilon$ Aca, Ach, Acp, Adpd, Ahb, Aib,  $\beta$ Aib, Ala,  $\beta$ Ala,  $\Delta$ Ala, Alg, All, Ama, Amt, Ape, Apm, Apr, Arg, Asn, Asp, Asu, Aze, Azi, Bai, Bph, Can, Cit, Cys, Cyta, Daad, Dab, Dadd, Dap, Dapm, Dasu, Djen, Dpa, Dtc, Fel, Gln, Glu, Gly, Guv, hAla, hArg, hCys, hGln, hGlu, His, hIle, hLeu, hLys, hMet, hPhe, hPro, hSer, hThr, hTrp, hTyr, Hyl, Hyp, 3Hyp, Ile, Ise, Iva, Kyn, Lant, Lcn, Leu, Lsg, Lys,  $\beta$ Lys,  $\Delta$ Lys, Met, Mim, Min, nArg, Nle, Nva, Oly, Orn, Pan, Pec, Pen, Phe, Phg, Pic, Pro, Pro, Pse, Pya, Pyr, Pza, Qin, Ros, Sar, Sec, Sem, Ser, Thi,  $\beta$ Thi, Thr, Thy, Thx, Tia, Tle, Tly, Trp, Trta, Tyr, Val.

Suitable radicals of a heterocyclic ring system of the formula IV are in particular radicals of heterocycles of the group below:







20 Pyrrolidine (A); piperidine (B); tetrahydroisoquinoline (C); decahydroisoquinoline (D); octahydroindole (E); octahydrocyclopenta[b]pyrrole (F); 2-aza-bicyclo[2.2.2]-octane (G); 2-azabicyclo[2.2.1]heptane (H); 2-azaspiro[4.5]decane (I); 2-azaspiro[4.4]nonane (J); spiro[(bi-

5      cyclo[2.2.1]heptane)-2,3-pyrrolidine] (K); spiro[(bi-  
cyclo[2.2.2]octane)-2,3-pyrrolidine] (L); 2-azatricyclo-  
[4.3.0.1<sup>5,9</sup>]decane (M); decahydrocyclohepta[b]pyrrole (N);  
octahydroisoindole (O); octahydrocyclopenta[c]pyrrole  
(P); 2,3,3a,4,5,7a-hexahydroindole (Q); tetrahydrothia-  
zole (R); 2-azabicyclo[3.1.0]hexane (S); isoxazolidine  
(T); pyrazolidine (U); hydroxyproline (V); all of which  
may be optionally substituted.

.....  
.....  
.....  
.....  
.....

.....  
.....  
.....  
.....

.....



The heterocycles based on the abovementioned radicals are known, for example, from

5 US-A-4,344,949, US-A-4,374,847, US-A-4,350,704,  
EP-A-50,800, EP-A-31,741, EP-A-51,020, EP-A-49,658,  
EP-A-49,605, EP-A-29,488, EP-A-46,953, EP-A-52,870,  
EP-A-271,865, DE-A-3,226,768, DE-A-3,151,690,  
DE-A-3,210,496, DE-A-3,211,397, DE-A-3,211,676,  
DE-A-3,227,055, DE-A-3,242,151, DE-A-3,246,503 and  
DE-A-3,246,757.

10      Some of these heterocycles are furthermore proposed in  
DE-A-3,818,850.3.

If not stated otherwise in the individual case, alkyl can be straight-chain or branched. The same applies to radicals derived therefrom such as alkoxy, aralkyl or alkanoyl.

(C<sub>6</sub>-C<sub>12</sub>)-Aryl preferably denotes phenyl, naphthyl or biphenyl. Radicals derived therefrom, such as aryloxy, aralkyl or aroyl, are to be formulated correspondingly.

20 Halo stands for fluorine, chlorine, bromine or iodine,  
preferably for chlorine.

Possible salts are, in particular, alkali metal or alkaline earth metal salts, salts with physiologically tolerable amines and salts with inorganic or organic acids such as, for example, HCl, HBr, H<sub>2</sub>SO<sub>4</sub>, H<sub>3</sub>PO<sub>4</sub>, maleic acid, fumaric acid, citric acid, tartaric acid and acetic acid.

Preferred peptides of the formula I are those in which

30 B denotes Arg, Lys, Orn, 2,4-diaminobutyroyl or an L-homoarginine radical, where in each case the amino or guanidino group of the side chain may be substituted by A as described under a<sub>1</sub>) or a<sub>2</sub>);



5 E stands for the radical of an aromatic amino acid in the L- or D-configuration, which contains 6 to 14 carbon atoms in the aryl moiety as ring members, such as phenylalanine which is optionally substituted by halogen in the 2-, 3- or 4-position, tyrosine, O-methyltyrosine, 2-thienylalanine, 2-pyridylalanine or naphthylalanine;

10 F' denotes the radical of a basic amino acid in the L- or D-configuration, such as Arg or Lys, where the guanidino group or amino group of the side chain may be replaced by A as described under a<sub>1</sub>) or a<sub>2</sub>), or denotes a radical -NH-(CH<sub>2</sub>)<sub>n</sub> - with n = 2 to 8 and

K stands for the radical -NH-(CH<sub>2</sub>)<sub>x</sub>-CO- with x = 2-4 or denotes a direct bond.

15 Particularly preferred peptides of the formula I are those in which

20 B denotes Arg, Orn or Lys, where the guanidino group or the amino group of the side chain is unsubstituted or may be substituted by (C<sub>1</sub>-C<sub>8</sub>)-alkanoyl, (C<sub>7</sub>-C<sub>13</sub>)-aryloyl, (C<sub>3</sub>-C<sub>9</sub>)-heteroaryloyl, (C<sub>1</sub>-C<sub>8</sub>)-alkylsulfonyl or (C<sub>6</sub>-C<sub>12</sub>)-arylsulfonyl, where the aryl, heteroaryl, aryloyl, arylsulfonyl and heteroaryloyl radicals may optionally be substituted, as described under a<sub>2</sub>), with 1, 2, 3 or 4 identical or different radicals.

25 E denotes phenylalanine, 2-chlorophenylalanine, 3-chlorophenylalanine, 4-chlorophenylalanine, 2-fluorophenylalanine, 3-fluorophenylalanine, 4-fluorophenylalanine, tyrosine, O-methyltyrosine or β-(2-thienyl)alanine;

30 K stands for a direct bond and

M stands for a direct bond

Very particularly preferred peptides of the formula I are those in which

- A denotes hydrogen, (D)- or (L)-H-Arg, (D)- or (L)-H-Lys or (D)- or (L)-H-Orn,
- 5 B denotes Arg, Orn or Lys, where the guanidino group or the amino group of the side chain may be substituted by hydrogen, (C<sub>1</sub>-C<sub>8</sub>)-alkanoyl, (C<sub>7</sub>-C<sub>13</sub>)-aryloyl, (C<sub>3</sub>-C<sub>9</sub>)-heteroaryloyl, (C<sub>1</sub>-C<sub>8</sub>)-alkylsulfonyl or (C<sub>6</sub>-C<sub>12</sub>)-arylsulfonyl, where the aryl, heteroaryl, arylloyl, arylsulfonyl and heteroaryloyl radicals may optionally be substituted with 1, 2, 3 or 4 identical or different radicals from the series comprising methyl, methoxy and halogen.
- 10 C denotes Pro-Pro-Gly, Hyp-Pro-Gly or Pro-Hyp-Gly
- 15 E denotes Phe or Thia
- F denotes Ser, Hser, Lys, Leu, Val, Nle, Ile or Thr
- K stands for a direct bond
- M stands for a direct bond
- 20 G stands for the radical of a heterocyclic ring system of the formula IV, where the radicals of the heterocycles pyrrolidine (A); piperidine (B); tetrahydroisoquinoline (C); cis- and trans-decahydroisoquinoline (D); cis-endo-octahydroindole (E), cis-exo-octahydroindole (E), trans-octahydroindole (E), cis-endo-, cis-exo-, trans-octahydrocyclopentano[b]pyrrole, (E) or hydroxyproline (V) are preferred.
- 25 F' denote Arg and
- I stands for OH.

Examples of very particularly preferred peptides of the

formula I are:

H-(D)-Arg-Arg-Pro-Hyp-Gly-Thia-Ser-(D)-Tic-Oic-Arg-OH  
H-(D)-Arg-Arg-Pro-Pro-Gly-Thia-Ser-(D)-Tic-Oic-Arg-OH  
H-(D)-Arg-Arg-Pro-Hyp-Gly-Phe-Ser-(D)-Tic-Oic-Arg-OH  
H-(D)-Arg-Arg-Hyp-Pro-Gly-Phe-Ser-(D)-Tic-Oic-Arg-OH  
H-(D)-Arg-Arg-Pro-Pro-Gly-Phe-Ser-(D)-Tic-Oic-Arg-OH

The invention furthermore relates to a process for the preparation of peptides of the formula I, which comprises

- a) reacting a fragment having a C-terminal free carboxyl group or its activated derivative with an appropriate fragment having an N-terminal free amino group or
- b) synthesizing the peptide stepwise, optionally splitting off one or more protective groups temporarily introduced for the protection of other functions in the compound obtained according to (a) or (b) and optionally converting the compounds of the formula I thus obtained into their physiologically tolerable salt.

The peptides of the present invention were prepared by generally known methods of peptide chemistry, see, for example, Houben-Weyl, Methoden der organischen Chemie (Methods of Organic Chemistry), Volume 15/2, preferably by means of solid phase synthesis such as described, for example, by B. Merrifield, J. Am. Chem. Soc. 85, 2149 (1963) or R. C. Sheppard, Int. J. Peptide Protein Res. 21, 118 (1983) or by equivalent known methods. Urethane protective groups such as, for example, the tert-butyloxycarbonyl(Boc) or fluorenylmethoxycarbonyl(Fmoc) protective group are used as  $\alpha$ -amino protective group. If necessary for the prevention of side reactions or for the synthesis of specific peptides, the functional groups in the side chain of amino acids are additionally protected by suitable protective groups (see, for example, T.W. Greene, "Protective Groups in Organic Synthesis"), where

primarily,

Arg(Tos), Arg(Mts), Arg(Mtr), Arg(PMC), Asp(OBzl),  
Asp(Obut), Cys(4-MeBzl), Cys(Acm), Cys(SBut), Glu(OBzl),  
Glu(Obut), His(Tos), His(Fmoc), His(Dnp), His(Trt),  
5 Lys(Cl-Z), Lys(Boc), Met(O), Ser(Bzl), Ser(But), Thr-  
(Bzl), Thr(But), Trp(Mts), Trp(CHO), Tyr(Br-Z), Tyr(Bzl)  
or Tyr(But) are employed.

10 Solid phase synthesis begins at the C-terminal end of the  
peptide with the coupling of a protected amino acid to an  
appropriate resin. Starting materials of this type may be  
obtained by linking a protected amino acid via an ester  
or amide bond to a polystyrene or polyacrylamide resin  
modified with a chloromethyl, hydroxymethyl, benzhydryl-  
amino(BHA) or methylbenzhydrylamino(MBHA) group. The  
resins used as support materials are commercially obtain-  
able. BHA and MBHA resins are usually used if the peptide  
synthesized is intended to have a free amide group at the  
C-terminus. If the peptide is intended to have a second-  
ary amide group at the C-terminal end, a chloromethyl or  
hydroxymethyl resin is used and the splitting off is  
carried out using the corresponding amines. If it is  
wished to obtain, for example, the ethylamide, the  
peptide can be split off from the resin using ethylamine,  
the splitting off of the side chain protective groups  
subsequently being carried out by means of other suitable  
reagents. If it is intended to retain the tert-butyl  
protective groups of the amino acid side chain in the  
peptide, the synthesis is carried out using the Fmoc  
protective group for temporary blocking of the  $\alpha$ -amino  
group of the amino acid using the method described, for  
example, in R.C. Sheppard, J.Chem.Soc., Chem.Comm 1982,  
587, the guanidino function of the arginine being protec-  
ted by protonation with pyridinium perchlorate and the  
protection of the other functionalized amino acids in the  
side chain being carried out using benzyl protective  
groups which can be split off by means of catalytic  
transfer hydrogenation (A. Felix et al. J. Org. Chem. 13,  
4194 (1978) or by means of sodium in liquid ammonia

(W. Roberts, J.Am.Chem.Soc. 76, 6203 (1954)).

After splitting off the amino protective group of the amino acid coupled to the resin using a suitable reagent, such as, for example, trifluoroacetic acid in methylene chloride in the case of the Boc protective group or a 20% strength solution of piperidine in dimethylformamide in the case of the Fmoc protective group, the subsequently protected amino acids are successively coupled in the desired sequence. The intermediately resulting N-terminal protected peptide resins are deblocked by means of the reagents described above before linkage with the subsequent amino acid derivative.

All possible activating reagents used in peptide synthesis can be used as coupling reagents, see, for example, Houben-Weyl, Methoden der organischen Chemie (Methods of Organic Chemistry), Volume 15/2, in particular, however, carbodiimides such as, for example, N,N'-dicyclohexylcarbodiimide, N,N'-diisopropylcarbodiimide or N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide. The coupling can in this case be carried out directly by addition of amino acid derivative and the activating reagent and, if desired, a racemization-suppressing additive such as, for example, 1-hydroxy-benzotriazole (HOBt) (W. König, R. Geiger, Chem. Ber. 103, 708 (1970)) or 3-hydroxy-4-oxo-3,4-dihydrobenzo-triazine (HOObt) (W. König, R. Geiger, Chem. Ber. 103, 2054 (1970)) to the resin or, however, the preactivation of the amino acid derivative as symmetrical anhydride or HOBt or HOObt ester can be carried out separately and the solution of the activated species in a suitable solvent can be added to the peptide resin capable of coupling.

35 The coupling or activation of the amino acid derivative with one of the abovementioned activating reagents can be carried out in dimethylformamide, N-methylpyrrolidone or methylene chloride or a mixture of the solvents mentioned. The activated amino acid derivative is

customarily employed in a 1.5 to 4 fold excess. In cases in which an incomplete coupling takes place, the coupling reaction is repeated without previously carrying out the deblocking of the  $\alpha$ -amino group of the peptide resin necessary for the coupling of the following amino acid.

The successful course of the coupling reaction can be monitored by means of the ninhydrin reaction, such as described, for example, by E. Kaiser et al. Anal. Biochem. 34 595 (1970). The synthesis can also be automated, for example using a peptide synthesizer model 430A from Applied Biosystems, it being possible either to use the synthesis program provided by the apparatus manufacturer or else, however, one set up by the user himself. The latter are in particular employed in the use of amino acid derivatives protected with the Fmoc group.

After synthesis of the peptides in the previously described manner, the peptide can be split off from the resin using reagents, such as, for example, liquid hydrogen fluoride (preferably in the peptides prepared according to the Boc method) or trifluoroacetic acid (preferably in the peptides synthesized according to the Fmoc method). These reagents not only cleave the peptide from the resin but also the other side chain protective groups of the amino acid derivative. In this manner, the peptide is obtained in the form of the free acid in addition using BHA and MBHA resins. With the BHA or MBHA resins, the peptide is obtained as acid amide when splitting off is carried out using hydrogen fluoride or trifluoromethanesulfonic acid. Additional processes for the preparation of peptide amides are described in German Patent Applications P 37 11 866.8 and P 37 43 620.1. The splitting off of the peptide amides from the resin here is carried out by treatment with medium strength acids (for example trifluoroacetic acid) usually used in peptide synthesis, cation entrainer substances such as phenol, cresol, thiocresol, anisole, thioanisole, ethanedithiol, dimethyl sulfide, ethyl methyl sulfide or

similar cation entrainers customary in solid phase synthesis being added individually or as a mixture of two or more of these auxiliaries. In this case, the trifluoroacetic acid can also be used diluted by suitable solvents, such as, for example, methylene chloride.

If the tert-butyl or benzyl side chain protective groups of the peptides are to be retained, the splitting off of the peptide synthesized on a particularly modified support resin is carried out using 1% trifluoroacetic acid in methylene chloride, such as described, for example, in R.C. Sheppard J.Chem. Soc., Chem. Comm. 1982, 587. If individual tert-butyl or benzyl side chain protective groups are to be retained, a suitable combination of synthesis and splitting off methods is used.

For the synthesis of peptides having a C-terminal amide grouping or an  $\omega$ -amino or  $\omega$ -guanidinoalkyl grouping, the modified support resin described by Sheppard is likewise used. After the synthesis, the peptide fully protected in the side chain is split off from the resin and subsequently reacted with the appropriate amine or  $\omega$ -aminoalkylamine or  $\omega$ -guanidinoalkylamine in classical solution synthesis, it being possible for optionally present additional functional groups to be temporarily protected in a known manner.

An additional process for the preparation of peptides having an  $\omega$ -aminoalkyl grouping is described in German Patent Application P 36 35 670.0.

The peptides of the present invention were preferably synthesized by two general protective group tactics using the solid phase technique:

The synthesis was carried out using an automatic peptide synthesizer model 430 A from Applied Biosystems, with Boc or Fmoc protective groups for temporary blockage of the



$\alpha$ -amino group.

When using the Boc protective group, the synthesis cycles pre-programmed by the manufacturer of the apparatus were used for the synthesis.

5 The synthesis of the peptides having a free carboxyl group on the C-terminal end was carried out on a 4-(hydroxymethyl)phenylacetamidomethylpolystyrene resin functionalized with the corresponding Boc amino acid (R.B. Merrifield, J. Org. Chem. 43, 2845 (1978)) from Applied Biosystems. An MBHA resin from the same firm was used for the preparation of the peptide amides.

10

N,N'-Dicyclohexylcarbodiimide or N,N'-diisopropylcarbodiimide were used as activating reagents. Activation was carried out as the symmetrical anhydride, as the HOBT ester or HOOBT ester in  $\text{CH}_2\text{Cl}_2$ ,  $\text{CH}_2\text{Cl}_2$  - DMF mixtures or NMP. 2-4 equivalents of activated amino acid derivative were employed for the coupling. In cases in which the coupling took place incompletely, the reaction was repeated.

15

During the use of the Fmoc protective group for the temporary protection of the  $\alpha$ -amino group, our own synthesis programs were used for synthesis using the automatic peptide synthesizer model 430A from Applied Biosystems. The synthesis was carried out on a p-benzyloxybenzyl alcohol resin (S. Wang, J. Am. Chem. Soc. 95, 1328 (1973)) from Bachem which was esterified by a known method (E. Atherton et al. J.C.S. Chem. Comm. 1981, 336) using the appropriate amino acid. The activation of the amino acid derivatives as HOBT or HOOBT esters was carried out directly in the amino acid cartridges provided by the apparatus manufacturer by addition of a solution of diisopropylcarbodiimide in DMF to the previously weighed-in mixture of amino acid derivative and HOBT or HOOBT. Fmoc-amino acid-OOBT esters prepared in substance can likewise be employed as described in European Patent Application 87,107,634.5. The splitting

30

35



off of the Fmoc protective group was carried out using a 20% strength solution of piperidine in DMF in the reaction vessel. The excess of reactive amino acid derivative used was 1.5 to 2.5 equivalents. If the coupling was not complete, it was repeated as in the Boc method.

The peptides according to the invention have, individually or in combination, a bradykinin antagonist action which can be tested in various models (see Handbook of Exp. Pharmacol. Vol. 25, Springer Verlag, 1970, p. 53-55), for example on the isolated rat uterus, on the guinea pig ileum or on the isolated pulmonary artery of the guinea pig.

For testing the peptides according to the invention on the isolated arteria pulmonalis, guinea pigs (Dunkin Hartley) having a weight of 400 - 450 g are sacrificed by a blow to the back of the neck.

The thorax is opened and the arteria pulmonalis is carefully dissected out. The surrounding tissue is carefully removed and the arteria pulmonalis is cut spirally at an angle of 45°.

The vessel strip of 2.5 cm length and 3-4 mm width is fixed in a 10 ml capacity organ bath which is filled with Ringer solution.

Composition of the solution in mmol/l

NaCl	154
KCl	5.6
CaCl <sub>2</sub>	1.9
NaHCO <sub>3</sub>	2.4
Glucose	5.0

95% O<sub>2</sub> and 5% CO<sub>2</sub> is bubbled through the solution, which is warmed to 37°C. The pH is 7.4 and the preload on the vessel strip is 1.0 g.

The isotonic contraction changes are detected using a lever arrangement and an HF modem (position sensor) from Hugo Sachs and recorded on a compensating recorder (BEC, Goerz Metrawatt SE 460).

5 After equilibration for 1 hour, the experiment is begun.  
After the vessel strips have achieved their maximum  
sensitivity to  $2 \times 10^{-7}$  mol/l of bradykinin - bradykinin  
leads to a contraction of the vessel strips - the pep-  
tides are allowed to act for 10 minutes in each case in  
10 the doses  $5 \times 10^{-8}$  -  $1 \times 10^{-5}$  mol/l and, after adding  
bradykinin again, the decrease in the effect of bradykin-  
in as opposed to the control is compared.

For the detection of a partial agonistic effect, the  
peptides are used in the doses  $1 \times 10^{-5}$  -  $1 \times 10^{-3}$  mol/l.

15 The  $IC_{50}$  values of the peptides according to the invention  
calculated from the dose-effect curves are shown in Table  
1.

Table 1:

Compound	$IC_{50}$ [M]
H-(D)-Arg-Arg-Hyp-Pro-Gly-Phe-Ser-(D)-Tic-Phe-Arg-OH	$4,6 \cdot 10^{-6}$
H-(D)-Arg-Arg-Hyp-Pro-Gly-Thia-Ser-(D)-Tic-Thia-Arg-OH	$2,1 \cdot 10^{-6}$
H-(D)-Arg-Arg-Pro-Hyp-Gly-Phe-Ser-(D)-Tic-Phe-Arg-OH	$1,2 \cdot 10^{-5}$
H-(D)-Arg-Arg-Hyp-Pro-Gly-Phe-Glo-(D)-Tic-Phe-Arg-OH	$2,4 \cdot 10^{-5}$
25 H-(D)-Arg-Arg-Pro-Hyp-Gly-Phe-Ser-(D)-Tic-Phe-Arg(Mtr)-OH	$2,5 \cdot 10^{-5}$
H-(D)-Arg-Arg-Hyp-Pro-Gly-Phe-Ser-(D)-Tic-Pro-Arg-OH	$2,5 \cdot 10^{-7}$
H-(D)-Arg-Arg-Hyp-Pro-Gly-Thia-Ser-(D)-Tic-Pro-Arg-OH	$1,9 \cdot 10^{-7}$
H-(D)-Arg-Arg-Hyp-Pro-Gly-Thia-Ser-(D)-Tic-Aoc-Arg-OH	$5,6 \cdot 10^{-8}$
H-(D)-Arg-Arg-Hyp-Pro-Gly-Thia-Ser- $\beta$ -Ala-(D)-Tic-Aoc-Arg-OH	$1,7 \cdot 10^{-6}$
30 H-(D)-Arg-Arg-Hyp-Pro-Gly-Thia-Ser-Gly-(D)-Tic-Aoc-Arg-OH	$3,9 \cdot 10^{-7}$
H-(D)-Arg-Arg-Hyp-Pro-Gly-Thia-Gly-(D)-Tic-(D,L)-Oic-Arg-OH	$3,2 \cdot 10^{-7}$
H-(D)-Arg-(D)-Arg-Hyp-Pro-Gly-Thia-Ser-(D)-Tic-Aoc-Arg-OH	$4,8 \cdot 10^{-7}$
H-(D)-Arg-Arg-Hyp-Pro-Gly-Thia-Ser-(D)-Tic-Tig-Arg-OH	$1,7 \cdot 10^{-7}$

Compound	IC <sub>50</sub> [M]
H-(D)-Arg-Arg-Pro-Hyp-Gly-Thia-Ser-(D)-Tic-Aoc-Arg-OH	1,1 · 10 <sup>-8</sup>
H-(D)-Arg-Arg-Pro-Hyp-Gly-Phe-Ser-(D)-Tic-Aoc-Arg-OH	4,6 · 10 <sup>-8</sup>
5 H-(D)-Tyr-Arg-Pro-Hyp-Gly-Thia-Ser-(D)-Tic-Aoc-Arg-OH	6,2 · 10 <sup>-8</sup>
H-(D)-Arg-Arg-Pro-Hyp-Gly-Thia-Ser-(D)-Tic-(D)-Dic-Arg-OH	2,6 · 10 <sup>-5</sup>
H-(D)-Arg-Arg-Pro-Hyp-Gly-Thia-Ser-(D)-Tic-Oic-Arg-OH	5,4 · 10 <sup>-9</sup>
H-(D)-Arg-Lys-Pro-Hyp-Gly-Phe-Ser-(D)-Tic-Aoc-Arg-OH	3,2 · 10 <sup>-7</sup>
H-(D)-Arg-Arg-Pro-Hyp-Gly-Phe-Ser-(D)-Tic-Oic-Arg-OH	6,8 · 10 <sup>-9</sup>
10 H-(D)-Arg-Arg-(NO <sub>2</sub> )-Pro-Hyp-Gly-Phe-Ser-(D)-Tic-Aoc-Arg-OH	6,4 · 10 <sup>-8</sup>
H-(D)-Arg-Arg-Pro-Pro-Gly-Thia-Ser-(D)-Tic-Oic-Arg-OH	4,2 · 10 <sup>-9</sup>
H-(D)-Arg-Pro-Hyp-Gly-Phe-Ser-(D)-Tic-Oic-Arg-OH	3,4 · 10 <sup>-7</sup>
H-Arg-(Tos)-Pro-Hyp-Gly-Phe-Ser-(D)-Tic-Dic-Arg-OH	3,0 · 10 <sup>-8</sup>
H-Arg-(Tos)-Pro-Hyp-Gly-Thia-Ser-(D)-Tic-Dic-Arg-OH	1,8 · 10 <sup>-8</sup>

The therapeutic utility of the peptides according to the invention includes all pathological states which are mediated, caused or supported by bradykinin and bradykinin-related peptides. This includes, inter alia, traumas, such as wounds, burns, rashes, erythemas, edemas, angina, arthritis, asthma, allergies, rhinitis, shock, inflammations, low blood pressure, pain, itching and changed sperm motility.

The invention therefore also relates to the use of peptides of the formula I as medicaments, and to pharmaceutical preparations which contain these compounds.

Pharmaceutical preparations contain an effective amount of the active substance of the formula I - individually or in combination - together with an inorganic or organic pharmaceutically utilizable excipient.

Administration can be carried out enterally, parenterally - such as, for example, subcutaneously, i.m. or i.v. -, sublingually, epicutaneously, nasally, rectally, intravaginally, intrabuccally or by inhalation. The dosage of the active substance depends on the mammal species, the body weight, age and on the manner of administration.

The pharmaceutical preparations of the present invention are prepared in solution, mixing, granulating or tablet coating processes known per se.

5 For oral administration or application to the mucosa, the active compounds are mixed with the customary additives for this, such as excipients, stabilizers or inert diluents, and brought into suitable forms for administration, such as tablets, coated tablets, hard gelatin capsules, aqueous, alcoholic or oily suspensions or  
10 aqueous, alcoholic or oily solutions, by customary methods. Inert excipients which may be used are, for example, gum arabic, magnesia, magnesium carbonate, potassium phosphate, lactose, glucose, magnesium stearyl fumarate or starch, in particular maize starch. In this  
15 case, the preparation may be present both as dry and moist granules. Suitable oily excipients or solvents are, for example, vegetable or animal oils, such as sunflower oil and cod liver oil.

20 A preparation for topical application may be present as an aqueous or oily solution, lotion, emulsion or gel, ointment or fatty ointment or, if possible, in spray form, it being possible to improve the adhesion, if desired, by addition of a polymer.

25 For the intranasal form of administration, the compounds are mixed with the customary auxiliaries for this, such as stabilizers or inert diluents, and brought into suitable forms for administration, such as aqueous, alcoholic or oily suspensions or aqueous, alcoholic or oily solutions, by customary methods. Chelating agents, ethylenediamine-N,N,N',N'-tetraacetic acid, citric acid,  
30 tartaric acid or their salts may be added to aqueous intranasal preparations. Administration of the nasal solutions can be carried out by means of metered atomizers or as nasal drops, having a viscosity-increasing component, or nasal gels or nasal creams.  
35

For administration by inhalation, atomizers or pressurized gas packs using inert carrier gases can be used.

5 For intravenous, subcutaneous, epicutaneous or intra-  
dermal administration, the active compounds or their  
physiologically tolerable salts, if desired with the  
pharmaceutically customary auxiliaries, for example for  
isotonisizing or adjusting pH, and solubilizers, emul-  
sifiers or other auxiliaries, are brought into solution,  
10 suspension or emulsion.

15 Because of the short half-lives of some of the medica-  
ments described in body fluids, the use of injectable  
sustained release preparations is efficient. Medicament  
forms which may be used are, for example, oily crystal  
suspensions, microcapsules, rods or implants, it being  
possible to synthesize the latter from tissue-compatible  
polymers, in particular biodegradable polymers, such as,  
for example, those based on polylactic acid/ polyglycolic  
acid copolymers or human albumin.

20 A suitable dose range for forms for topical application  
and administration by inhalation are solutions containing  
0.01-5 mg/ml, and with forms for systemic administration  
0.01-10 mg/kg is suitable.

25 List of abbreviations:

The abbreviations used for amino acids correspond to the  
three-letter code customary in peptide chemistry as  
described in Europ. J. Biochem. 138, 9 (1984). Addition-  
ally used abbreviations are listed below.

30	AcM	Acetamidomethyl
	ε-Ahx	ε-Aminohexanoyl
	Aoc	cis, endo-2-Azabicyclo[3.3.0]octane-3-S- carbonyl
	Boc	tert-Butyloxycarbonyl
	But	tert-Butyl

	Bzl	Benzyl
	Cl-Z	4-Chlorobenzyloxycarbonyl
	DMF	Dimethylformamide
	Dnp	2,4-Dinitrophenyl
5	Fmoc	9-Fluorenylmethoxycarbonyl
	Me	Methyl
	4-Mebzl	4-Methylbenzyl
	Mtr	4-Methoxy-2,3,6-trimethylphenylsulfonyl
	Mts	Mesitylene-2-sulfonyl
10	NMP	N-Methylpyrrolidine
	Oic	cis-endo-octahydroindol-2-ylcarbonyl
	Opr	Isoxazolidin-3-ylcarbonyl
	Pmc	2,2,5,7,8-Pentamethylchroman-6-sulfonyl
	TFA	Trifluoroacetic acid
15	Tcs	4-Methylphenylsulfonyl
	Thia	2-Thienylalanyl
	Tic	1,2,3,4-Tetrahydroisoquinolin-3-ylcarbonyl
	Trt	Trityl

The following examples are intended to illustrate the preferred methods for solid phase synthesis of the peptides according to the invention, without limiting the invention thereto.

The amino acid derivatives below were used:

Fmoc-Arg(Mtr)-OH, Boc-(D)-Arg-OH, Fmoc-Arg(Pmc)-OH, Fmoc-Hyp-OH, Fmoc-Pro-OObt, Fmoc-Gly-OObt, Fmoc-Phe-OObt, Fmoc-Ser(tBu)-OObt, Fmoc-(D)-Tic-OH, Fmoc-Gln-OH, Fmoc-Aoc-OH, Fmoc-Thia-OH, Fmoc-Opr-OH, Fmoc-(D)-Asn-OH, Fmoc-β-Ala-OH, Fmoc-Oic-OH.

#### Example 1:

H-(D)-Arg-Arg-Hyp-Pro-Gly-Phe-Ser-(D)-Tic-Phe-Arg-OH was synthesized stepwise using a peptide synthesizer model 430 A from Applied Biosystems by the Fmoc method on a p-benzyloxybenzyl alcohol resin from Novabiochem (loading about 0.5 mmol/g of resin) esterified with Fmoc-Arg(Mtr)-OH. 1 g of the resin was employed and the

synthesis was carried out with the aid of a synthesis program modified for the Fmoc method.

5 In each case 1 mmol of the amino acid derivative having a free carboxyl group together with 0.95 mmol of HOOBt was weighed into the cartridges of the synthesizer. The preactivation of these amino acids was carried out directly in the cartridges by dissolving in 4 ml of DMF and adding 2 ml of a 0.55 mol solution of diisopropylcarbodiimide in DMF.

10 The HOOBt esters of the other amino acids were dissolved in 6 ml of NMP and then similarly coupled to the resin previously deblocked using 20% piperidine in DMF, like the amino acids preactivated in situ. After completion of the synthesis, the peptide was split off from the resin  
15 using thioanisole and ethanedithiol as cation entrainers, with simultaneous removal of the side chain protective groups using trifluoroacetic acid. The residue obtained after stripping off the trifluoroacetic acid was repeatedly digested with ethyl acetate and centrifuged. The  
20 residue which remained was chromatographed on  $\text{Sephadex LH 20}$  using 10% strength acetic acid. The fractions containing the pure peptide were combined and freeze-dried.

MS(FAB) : 1294 (M+H)

25 The peptides of Examples 2 to 24 below were prepared and purified analogously to Example 1.

Example 2:

H-(D)-Arg-Arg-Hyp-Pro-Gly-Phe-(D)-Ser-(D)-Tic-Phe-Arg-OH  
MS(FAB) : 1294 (M+H)

Example 3:

H-(D)-Arg-Arg-Hyp-Pro-Gly-Thia-Ser-(D)-Tic-Thia-Arg-OH  
MS(FAB) : 1306 (M+H)

**Example 4:**

H-(D)-Arg-Arg-Pro-Hyp-Gly-Phe-Ser-(D)-Tic-Phe-Arg-OH  
MS(FAB) : 1294 (M+H)

**Example 5:**

H-(D)-Arg-Arg-Hyp-Pro-Gly-Phe-Gln-(D)-Tic-Phe-Arg-OH  
MS(FAB) : 1335 (M+H)

**Example 6:**

H-(D)-Arg-Arg-Hyp-Pro-Gly-Phe-Ser-(D)-Tic-Pro-Arg-OH  
MS(FAB) : 1244 (M+H)

**Example 7:**

H-(D)-Arg-Arg-Hyp-Pro-Gly-Phe-Trp-(D)-Tic-Phe-Arg-OH  
MS(FAB) : 1393 (M+H)

5

**Example 8:**

H-(D)-Arg-Arg-Hyp-Pro-Gly-Thia-Ser-(D)-Tic-Pro-Arg-OH  
MS(FAB) : 1250 (M+H)

**Example 9:**

H-(D)-Arg-Arg-Hyp-Pro-Gly-Thia-(D)-Asn-(D)-Tic-Thia-Arg-OH  
MS(FAB) : 1333 (M+H)

**Example 10:**

H-(D)-Arg-Arg-Hyp-Pro-Gly-Thia-Opr-(D)-Tic-Thia-Arg-OH  
MS(FAB) : 1301 (M+H)

**Example 11:**

H-(D)-Arg-Arg-Hyp-Pro-Gly-Thia-(D)-Gln-(D)-Tic-Thia-Arg-OH  
MS(FAB) : 1347 (M+H)

**Example 12:**

H-(D)-Arg-Arg-Hyp-Pro-Gly-Thia-Ser-Gly-(D)-Tic-Pro-Arg-OH  
MS(FAB) : 1307 (M+H)

10

**Example 13:**

H-(D)-Arg-Arg-Hyp-Pro-Gly-Thia-Ser-(D)-Tic-Pro-Phe-OH  
MS(FAB) : 1241 (M+H)



**Example 14:**

H-(D)-Arg-Arg-Hyp-Pro-Gly-Thia-Ser-(D)-Tic-Pro-Phe-Arg-OH  
MS(FAB) : 1397 (M+H)

**Example 15:**

H-(D)-Arg-Arg-Hyp-Pro-Gly-Thia-Ser-B-Ala-(D)-Tic-Pro-Arg-OH  
MS(FAB) : 1321 (M+H)

**Example 16:**

H-(D)-Arg-Arg-Hyp-Pro-Gly-Thia-Gly-(D)-Tic-Pro-Arg-OH  
MS(FAB) : 1220 (M+H)

**Example 17:**

H-(D)-Arg-Arg-Aoc-Pro-Gly-Thia-Ser-(D)-Tic-Thia-Arg-OH  
MS(FAB) : 1330 (M+H)

5

**Example 18:**

H-(D)-Arg-Arg-Pro-Aoc-Gly-Thia-Ser-(D)-Tic-Thia-Arg-OH  
MS(FAB) : 1330 (M+H)

**Example 19:**

H-(D)-Arg-Arg-Hyp-Pro-Gly-Thia-Ser-(D)-Tic-Aoc-Arg-OH  
MS(FAB) : 1290 (M+H)

**Example 20:**

H-(D)-Arg-Arg-Opr-Pro-Gly-Thia-Ser-(D)-Tic-Pro-Arg-OH  
MS(FAB) : 1236 (M+H)

**Example 21:**

H-(D)-Arg-Arg-Pro-Opr-Gly-Thia-Ser-(D)-Tic-Pro-Arg-OH  
MS(FAB) : 1236 (M+H)

**Example 22:**

H-(D)-Arg-Arg-Hyp-Pro-Gly-Thia-Ser-(D)-Tic-Opr-Arg-OH  
MS(FAB) : 1252 (M+H)

10

**Example 23:**

H-(D)-Arg-(D)-Arg-Hyp-Pro-Gly-Thia-Ser-(D)-Tic-Aoc-Arg-OH  
MS(FAB) : 1290 (M+H)

**Example 24:**

H-(D)-Arg-Arg-Pro-Hyp-Gly-Thia-Ser-(D)-Tic-Aoc-Arg-OH  
MS(FAB) : 1290 (M+H)

**Examples 25 - 27:**

H-(D)-Arg-Arg(Mtr)-Pro-Hyp-Gly-Phe-Ser-(D)-Tic-Phe-Arg-OH

5 and

H-(D)-Arg-Arg-Pro-Hyp-Gly-Phe-Ser-(D)-Tic-Phe-Arg(Mtr)-OH

and

10 H-(D)-Arg-Arg(Mtr)-Pro-Hyp-Gly-Phe-Ser-(D)-Tic-Phe-Arg(Mtr)-OH

are prepared analogously to Example 1, the splitting off of the side chain protective groups and the peptide from the resin by means of trifluoroacetic acid being limited to 30 minutes at room temperature. Under the conditions thus selected, only a negligible splitting off of the Mtr protective group on the arginine takes place. The partially deblocked peptides are separated by chromatography on reverse phase material and purified.

15  
20 25: H-(D)-Arg-Arg(Mtr)-Pro-Hyp-Gly-Phe-Ser-(D)-Tic-Phe-Arg-OH

MS(FAB): 1506 (M+H)

26: H-(D)-Arg-Arg(Mtr)-Pro-Hyp-Gly-Phe-Ser-(D)-Tic-Phe-Arg(Mtr)-OH

MS(FAB): 1718 (M+H)

25 27: H-(D)-Arg-Arg-Pro-Hyp-Gly-Phe-Ser-(D)-Tic-Phe-Arg(Mtr)-OH

MS(FAB): 1506 (M+H)

The peptides of Examples 28 - 31 below were prepared and purified analogously to Examples 25 - 27.

**Example 28:**

H-(D)-Arg-Arg(Mtr)-Hyp-Pro-Gly-Thia-Ser-(D)-Tic-Pro-Arg-OH  
MS(FAB) : 1462 (M+H)

Example 29:

H-(D)-Arg-Arg-Hyp-Pro-Gly-Thia-Ser-(D)-Tic-Pro-Arg(Mtr)-OH  
MS(FAB) : 1462 (M+H)

Example 30:

H-(D)-Arg-Arg(Mtr)-Hyp-Pro-Gly-Thia-Ser-(D)-Tic-Pro-Phe-OH  
MS(FAB) : 1453 (M+H)


Example 31:

H-(D)-Arg-Arg(Mtr)-Hyp-Pro-Gly-Thia-Ser-(D)-Tic-Aoc-Arg-OH  
MS(FAB) : 1502 (M+H)

Example 32:

5 H-Arg-Hyp-Pro-Gly-Phe-Ser-(D)-Tic-Phe-NH-(CH<sub>2</sub>)<sub>4</sub>-NH<sub>2</sub>.

The peptide synthesis was carried out on 1 g of an amino-methyl resin which was modified with an attachment group of the type



described in EP-A 264,802, using Fmoc-amino acid-OObt esters with an automatic peptide synthesizer (model 430A from Applied Biosystems) and synthesis programs which have themselves been modified. To this end, in each case 1 mmol of the appropriate amino acid derivative was weighed into the cartridges provided by the manufacturer, and Fmoc-Arg(Mtr)-OH, Fmoc-Hyp-OH and Fmoc-(D)-Tic-OH were weighed into the cartridges together with 0.95 mmol of HOObt. The preactivation of these amino acids in situ was carried out directly in the cartridges by dissolving in 4 ml of DMF and adding 2 ml of a 0.55 M solution of diisopropylcarbodiimide in DMF. The HOObt esters of the other amino acids were dissolved in 6 ml of NMP and then coupled to the resin previously deblocked using 20% piperidine in DMF, like the amino acids preactivated in situ, the amino acids activated in situ being doubly coupled. After completion of synthesis, the peptide 4-

aminobutylamide was split off from the resin with simultaneous removal of the side chain protective groups with trifluoroacetic acid which contained thioanisole and m-cresol as cation entrainers. The residue obtained after stripping off the trifluoroacetic acid was repeatedly digested with ethyl acetate and centrifuged. The crude peptide which remained was chromatographed on <sup>®</sup>Sephadex G25 using 1N acetic acid. The fractions containing the pure peptide were combined and freeze-dried.

10 The compounds of Examples 33 - 35 were prepared analogously to Example 32:

Example 33:

H-D-Arg-Arg-Hyp-Fro-Gly-Phe-Ser-(D)-Tic-Phe-NH-(CH<sub>2</sub>)<sub>4</sub>-NH<sub>2</sub>

Example 34:

HOOC-(CH<sub>2</sub>)<sub>2</sub>-CO-Arg-Hyp-Pro-Gly-Phe-Ser-(D)-Tic-Phe-NH-(CH<sub>2</sub>)<sub>4</sub>-NH<sub>2</sub>

Example 35:

HOOC-(CH<sub>2</sub>)<sub>2</sub>-CO-(D)-Arg-Hyp-Pro-Gly-Phe-Ser-(D)-Tic-Phe-NH-(CH<sub>2</sub>)<sub>4</sub>-NH<sub>2</sub>

15 The examples 36 to 161 were synthesized according to the method described under Example 1.

Example 36:

H-(D)-Arg-Arg-Hyp-Pro-Gly-Thia-Ser-Gly-(D)-Tic-Pro-Arg-OH  
MS(FAB) : 1307 (M+H)

Example 37:

H-(D)-Arg-Arg-Pro-Hyp-Gly-Thia-Ser-Gly-(D)-Tic-Pro-Arg-OH  
MS(FAB) : 1307 (M+H)

Example 38:

H-(D)-Arg-Arg-Hyp-Pro-Gly-Thia-Ser-(D)-Tic-Pro-Phe-OH  
MS(FAB) : 1241 (M+H)

**Example 39:**

H-(D)-Arg-Arg-Hyp-Pro-Gly-Thia-Ser- $\beta$ -Ala-(D)-Tic-Aoc-Arg-OH  
MS(FAB) : 1361 (M+H)

**Example 40:**

H-(D)-Arg-Arg-Pro-Hyp-Gly-Thia-Ser- $\beta$ -Ala-(D)-Tic-Aoc-Arg-OH  
MS(FAB) : 1361 (M+H)

**Example 41:**

H-(D)-Arg-Arg-Hyp-Pro-Gly-Thia-Ser-(D)-Tic-Pro-Phe-Arg-OH  
MS(FAB) : 1397 (M+H)

**Example 42:**

H-(D)-Arg-Arg-Pro-Hyp-Gly-Thia-Ser-(D)-Tic-Pro-Phe-Arg-OH  
MS(FAB) : 1397 (M+H)

5 **Example 43:**

H-(D)-Arg-Arg-Pro-Hyp-Gly-Thia-Gly-(D)-Tic-Aoc-Arg-OH  
MS(FAB) : 1260 (M+H)

.. **Example 44:**

H-(D)-Arg-Arg-Hyp-Pro-Gly-Thia-Gly-(D)-Tic-Aoc-Arg-OH  
MS(FAB) : 1260 (M+H)

.. **Example 45:**

H-(D)-Arg-(D)-Arg-Hyp-Pro-Gly-Thia-Ser-(D)-Tic-Aoc-Arg-OH  
MS(FAB) : 1290 (M+H)

.. **Example 46:**

H-(D)-Arg-(D)-Arg-Pro-Hyp-Gly-Thia-Ser-(D)-Tic-Aoc-Arg-OH  
MS(FAB) : 1290 (M+H)

.. **Example 47:**

H-(D)-Arg-Arg-Hyp-Pro-Gly-Thia-Ser-(D)-Tic-Tic-Arg-OH  
MS(FAB) : 1312 (M+H)

0 **Example 48:**

H-(D)-Arg-Arg-Pro-Hyp-Gly-Thia-Ser-(D)-Tic-Tic-Arg-OH  
MS(FAB) : 1312 (M+H)

Example 49:

H-(D)-Arg-Arg-Pro-Pro-Gly-Thia-Ser-(D)-Tic-Aoc-Arg-OH  
MS(FAB) : 1274 (M+H)

Example 50:

H-(D)-Arg-Arg-Hyp-Pro-Gly-Thia-(D)-Tic-Aoc-Arg-OH  
MS(FAB) : 1203 (M+H)

Example 51:

H-(D)-Arg-Arg-Hyp-Pro-Gly-Aoc-Ser-(D)-Tic-Aoc-Arg-OH  
MS(FAB) : 1274 (M+H)

Example 52:

H-(D)-Arg-Arg-Hyp-Pro-Gly-Thia-β-Ala-(D)-Tic-Aoc-Arg-OH  
MS(FAB) : 1274 (M+H)

Example 53:

H-(D)-Arg-Arg-Pro-Hyp-Gly-Thia-β-Ala-(D)-Tic-Aoc-Arg-OH  
MS(FAB) : 1274 (M+H)

Example 54:

H-(D)-Arg-Arg-Hyp-Pro-Gly-Asp-Ser-(D)-Tic-Aoc-Arg-OH  
MS(FAB) : 1252 (M+H)

Example 55:

H-(D)-Arg-Arg-Pro-Hyp-Gly-Asp-Ser-(D)-Tic-Aoc-Arg-OH  
MS(FAB) : 1252 (M+H)

Example 56:

H-(D)-Arg-Arg-Hyp-Pro-Gly-Trp-Ser-(D)-Tic-Aoc-Arg-OH  
MS(FAB) : 1323,7 (M+H)

Example 57:

H-(D)-Tyr-Arg-Pro-Hyp-Gly-Thia-Ser-(D)-Tic-Aoc-Arg-OH  
MS(FAB) : 1297,7 (M+H)

Example 58:

H-(D)-Arg-Arg-Pro-Hyp-Gly-Thia-Ser-(D)-Tic-(D)-Oic-Arg-OH  
MS(FAB) : 1304,6 (M+H)

**Example 59:**

H-(D)-Arg-Arg-Pro-Hyp-Gly-Thia-Ser-(D)-Tic-Oic-Arg-OH  
MS(FAB) : 1304,6 (M+H)

**Example 60:**

H-(D)-Arg-Arg-Pro-Pro-Gly-Thia-Ser-(D)-Tic-Oic-Arg-OH  
MS(FAB) : 1289 (M+H)

**Example 61:**

H-(D)-Arg-Lys-Pro-Hyp-Gly-Thia-Ser-(D)-Tic-Aoc-Arg-OH  
MS(FAB) : 1262 (M+H)

**Example 62:**

H-(D)-Arg-Lys-Pro-Hyp-Gly-Thia-Ser-(D)-Tic-Oic-Arg-OH  
MS(FAB) : 1276 (M+H)

**Example 63:**

H-(D)-Arg-Lys-Pro-Pro-Gly-Thia-Ser-(D)-Tic-Oic-Arg-OH  
MS(FAB) : 1260 (M+H)

**Example 64:**

H-(D)-Arg-Arg-Pro-Hyp-Gly-Phe-Ser-(D)-Tic-Oic-Arg-OH  
MS(FAB) : 1298 (M+H)

**Example 65:**

H-(D)-Arg-Arg-Hyp-Pro-Gly-Phe-Ser-(D)-Tic-Oic-Arg-OH  
MS(FAB) : 1298 (M+H)

**Example 66:**

H-(D)-Arg-Arg-Pro-Pro-Gly-Phe-Ser-(D)-Tic-Oic-Arg-OH  
MS(FAB) : 1282 (M+H)

**Example 67:**

H-(D)-Arg-Arg(NO<sub>2</sub>)-Pro-Hyp-Gly-Phe-Ser-(D)-Tic-Aoc-Arg-OH  
MS(FAB) : 1329,7 (M+H)

10

**Example 68:**

H-(D)-Arg-Arg(NO<sub>2</sub>)-Pro-Hyp-Gly-Phe-Ser-(D)-Tic-Oic-Arg-OH  
MS(FAB): 1343 (M+H)

**Example 69:**

H-(D)-Arg-Arg(NO<sub>2</sub>)-Pro-Pro-Gly-Phe-Ser-(D)-Tic-Oic-Arg-OH  
MS(FAB) : 1327 (M+H)

**Example 70:**

H-(D)-Arg-Arg(NO<sub>2</sub>)-Pro-Pro-Gly-Thia-Ser-(D)-Tic-Oic-Arg-OH  
MS(FAB) : 1333 (M+H)

**Example 71:**

H-(D)-Arg-Arg(NO<sub>2</sub>)-Pro-Hyp-Gly-Thia-Ser-(D)-Tic-Oic-Arg-OH  
MS(FAB) : 1349 (M+H)

**Example 72:**

H-Arg(Tos)-Pro-Hyp-Gly-Thia-Ser-D-Tic-Oic-Arg-OH  
MS(FAB) : 1302 (M+H)

**Example 73:**

H-Arg-Pro-Hyp-Gly-Phe-Ser-D-Tic-Oic-Arg-OH  
MS(FAB) : 1142 (M+H)

**Example 74:**

H-Lys(-CO-NH-C<sub>6</sub>H<sub>5</sub>)-Pro-Hyp-Gly-Phe-Ser-D-Tic-Oic-Arg-OH  
MS(FAB) : 1233 (M+H)

**Example 75:**

H-Arg(Tos)-Pro-Hyp-Gly-Phe-Ser-D-Tic-Oic-Arg-OH  
MS(FAB) : 1296 (M+H)

**Example 76:**

H-Lys(Nicotinoyl)-Pro-Hyp-Gly-Phe-Ser-D-Tic-Oic-Arg-OH  
MS(FAB) : 1219 (M+H)

**Example 77:**

H-Arg(Tos)-Pro-Hyp-Gly-Phe-Ser-D-Tic-Aoc-Arg-OH  
MS(FAB) : 1282 (M+H)



**Example 78:**

Ac-Arg(Tos)-Pro-Hyp-Gly-Phe-Ser-D-Tic-Aoc-Arg-OH  
MS(FAB) : 1324 (M+H)

**Example 79:**

H-D-Arg-Arg(Tos)-Pro-Hyp-Gly-Phe-Ser-D-Tic-Aoc-Arg-OH  
MS(FAB) : 1438 (M+H)

**Example 80:**

H-Arg(Tos)-Hyp-Pro-Gly-Thia-Ser-D-Tic-Oic-Arg-OH  
MS(FAB) : 1302 (M+H)

**Example 81:**

H-Arg-Hyp-Pro-Gly-Phe-Ser-D-Tic-Oic-Arg-OH  
MS(FAB) : 1142 (M+H)

**Example 82:**

H-Lys(-CO-NH-C<sub>6</sub>H<sub>5</sub>)-Hyp-Pro-Gly-Phe-Ser-D-Tic-Oic-Arg-OH  
MS(FAB) : 1233 (M+H)

**Example 83:**

H-Arg(Tos)-Hyp-Pro-Gly-Phe-Ser-D-Tic-Oic-Arg-OH  
MS(FAB) : 1296 (M+H)

**Example 84:**

H-Lys(Nicotinoyl)-Hyp-Pro-Gly-Phe-Ser-D-Tic-Oic-Arg-OH  
MS(FAB) : 1219 (M+H)

**Example 85:**

H-Arg(Tos)-Hyp-Pro-Gly-Phe-Ser-D-Tic-Aoc-Arg-OH  
MS(FAB) : 1282 (M+H)

**Example 86:**

Ac-Arg(Tos)-Hyp-Pro-Gly-Phe-Ser-D-Tic-Aoc-Arg-OH  
MS(FAB) : 1324 (M+H)

**Example 87:**

H-D-Arg-Arg(Tos)-Hyp-Pro-Gly-Phe-Ser-D-Tic-Aoc-Arg-OH  
MS(FAB) : 1438 (M+H)

**Example 88:**

H-Arg(Tos)-Pro-Pro-Gly-Thia-Ser-D-Tic-Oic-Arg-OH  
MS(FAB) : 1286 (M+H)

**Example 89:**

H-Arg-Pro-Pro-Gly-Phe-Ser-D-Tic-Oic-Arg-OH  
MS(FAB) : 1126 (M+H)

**Example 90:**

H-Lys(-CO-NH-C<sub>6</sub>H<sub>5</sub>)-Pro-Pro-Gly-Phe-Ser-D-Tic-Oic-Arg-OH  
MS(FAB) : 1217 (M+H)

**Example 91:**

H-Arg(Tos)-Pro-Pro-Gly-Phe-Ser-D-Tic-Oic-Arg-OH  
MS(FAB) : 1280 (M+H)

**Example 92:**

H-Lys(Nicotinoyl)-Pro-Pro-Gly-Phe-Ser-D-Tic-Oic-Arg-OH  
MS(FAB) : 1203 (M+H)

**Example 93:**

H-Arg(Tos)-Pro-Pro-Gly-Phe-Ser-D-Tic-Aoc-Arg-OH  
MS(FAB) : 1266 (M+H)

**Example 94:**

Ac-Arg(Tos)-Pro-Pro-Gly-Phe-Ser-D-Tic-Aoc-Arg-OH  
MS(FAB) : 1308 (M+H)

**Example 95:**

H-D-Arg-Arg(Tos)-Pro-Pro-Gly-Phe-Ser-D-Tic-Aoc-Arg-OH  
MS(FAB) : 1422 (M+H)

**Example 96:**

H-Arg-Pro-Hyp-Gly-Thia-Ser-D-Tic-Oic-Arg-OH  
MS(FAB) : 1148 (M+H)

**Example 97:**

H-Lys(-CO-NH-C<sub>6</sub>H<sub>5</sub>)-Pro-Hyp-Gly-Thia-Ser-D-Tic-Oic-Arg-OH  
MS(FAB) : 1239 (M+H)

**Example 98:**

H-Lys(Nicotinoyl)-Pro-Hyp-Gly-Thia-Ser-D-Tic-Oic-Arg-OH  
MS(FAB) : 1225 (M+H)

**Example 99:**

H-Arg(Tos)-Pro-Hyp-Gly-Thia-Ser-D-Tic-Aoc-Arg-OH  
MS(FAB) : 1288 (M+H)

**Example 100:**

Ac-Arg(Tos)-Pro-Hyp-Gly-Thia-Ser-D-Tic-Aoc-Arg-OH  
MS(FAB) : 1330 (M+H)

**Example 101:**

H-D-Arg-Arg(Tos)-Pro-Hyp-Gly-Thia-Ser-D-Tic-Aoc-Arg-OH  
MS(FAB) : 1444 (M+H)

**Example 102:**

H-Arg-Hyp-Pro-Gly-Thia-Ser-D-Tic-Oic-Arg-OH  
MS(FAB) : 1148 (M+H)

**Example 103:**

H-Lys(-CO-NH-C<sub>6</sub>H<sub>5</sub>)-Hyp-Pro-Gly-Thia-Ser-D-Tic-Oic-Arg-OH  
MS(FAB) : 1239 (M+H)

**Example 104:**

H-Lys(Nicotinoyl)-Hyp-Pro-Gly-Thia-Ser-D-Tic-Oic-Arg-OH  
MS(FAB) : 1225 (M+H)

**Example 105:**

H-Arg(Tos)-Hyp-Pro-Gly-Thia-Ser-D-Tic-Aoc-Arg-OH  
MS(FAB) : 1288 (M+H)

**Example 106:**

Ac-Arg(Tos)-Hyp-Pro-Gly-Thia-Ser-D-Tic-Aoc-Arg-OH  
MS(FAB) : 1330 (M+H)

**Example 107:**

H-D-Arg-Arg(Tos)-Hyp-Pro-Gly-Thia-Ser-D-Tic-Aoc-Arg-OH  
MS(FAB) : 1440 (M+H)

Example 108:

H-Lys(-CO-NH-C<sub>6</sub>H<sub>5</sub>)-Pro-Pro-Gly-Thia-Ser-D-Tic-Oic-Arg-OH  
MS(FAB) : 1225 (M+H)

Example 109:

H-Lys(Nicotinoyl)-Pro-Pro-Gly-Thia-Ser-D-Tic-Oic-Arg-OH  
MS(FAB) : 1209 (M+H)

Example 110:

H-Arg(Tos)-Pro-Pro-Gly-Thia-Ser-D-Tic-Aoc-Arg-OH  
MS(FAB): 1272 (M+H)

Example 111:

Ac-Arg(Tos)-Pro-Pro-Gly-Thia-Ser-D-Tic-Aoc-Arg-OH  
MS(FAB) : 1314 (M+H)

Example 112:

H-D-Arg-Arg(Tos)-Pro-Pro-Gly-Thia-Ser-D-Tic-Aoc-Arg-OH  
MS(FAB) : 1428 (M+H)

Example 113:

H-D-Arg-Lys(Nicotinoyl)-Pro-Pro-Gly-Thia-Ser-D-Tic-Oic-Arg-OH  
MS(FAB) : 1365 (M+H)

Example 114:

H-D-Arg-Lys(-CO-NH-C<sub>6</sub>H<sub>5</sub>)-Pro-Pro-Gly-Thia-Ser-D-Tic-Oic-Arg-OH  
MS(FAB) : 1379 (M+H)

Example 115:

H-D-Arg-Arg(Tos)-Pro-Pro-Gly-Thia-Ser-D-Tic-Oic-Arg-OH  
MS(FAB) : 1442 (M+H)

Example 116:

H-Lys-Lys-(Nicotinoyl)-Pro-Pro-Gly-Thia-Ser-D-Tic-Oic-Arg-OH  
MS(FAB) : 1337 (M+H)

**Example 117:**

H-Lys-Lys(-CO-NH-C<sub>6</sub>H<sub>5</sub>)-Pro-Pro-Gly-Thia-Ser-D-Tic-Oic-Arg-OH

MS(FAB) : 1351 (M+H)

**Example 118:**

H-Lys-Arg(Tos)-Pro-Pro-Gly-Thia-Ser-D-Tic-Oic-Arg-OH

MS(FAB) : 1414 (M+H)

**Example 119:**

H-D-Arg-Lys(Nicotinoyl)-Pro-Hyp-Gly-Thia-Ser-D-Tic-Oic-Arg-OH

MS(FAB) : 1381 (M+H)

**Example 120:**

H-D-Arg-Lys-(CO-NH-C<sub>6</sub>H<sub>5</sub>)-Pro-Hyp-Gly-Thia-Ser-D-Tic-Oic-Arg-OH

MS(FAB) : 1395 (M+H)

5

**Example 121:**

H-D-Arg-Arg(Tos)-Pro-Hyp-Gly-Thia-Ser-D-Tic-Oic-Arg-OH

MS(FAB) : 1458 (M+H)

**Example 122:**

H-Lys-Lys(-CO-NH-C<sub>6</sub>H<sub>5</sub>)-Pro-Hyp-Gly-Thia-Ser-D-Tic-Oic-Arg-OH

MS(FAB) : 1367 (M+H)

**Example 123:**

H-Lys-Lys(Nicotinoyl)-Pro-Hyp-Gly-Thia-Ser-D-Tic-Oic-Arg-OH

MS(FAB) : 1353 (M+H)

**Example 124:**

H-Lys-Arg(Tos)-Pro-Hyp-Gly-Thia-Ser-D-Tic-Oic-Arg-OH

MS(FAB) : 1430 (M+H)

**Example 125:**

H-D-Arg-Lys(Nicotinoyl)-Pro-Pro-Gly-Phe-Ser-D-Tic-Oic-Arg-OH

MS(FAB) : 1359 (M+H)

**Example 126:**

H-D-Arg-Lys(-CO-NH-C<sub>6</sub>H<sub>5</sub>)-Pro-Pro-Gly-Phe-Ser-D-Tic-Oic-Arg-OH

MS(FAB) : 1373 (M+H)

**Example 127:**

H-D-Arg-Arg(Tos)-Pro-Pro-Gly-Phe-Ser-D-Tic-Oic-Arg-OH

MS(FAB) : 1436 (M+H)

**Example 128:**

H-Lys-Lys(Nicotinoyl)-Pro-Pro-Gly-Phe-Ser-D-Tic-Oic-Arg-OH

MS(FAB) : 1331 (M+H)

**Example 129:**

H-Lys-Lys(-CO-NH-C<sub>6</sub>H<sub>5</sub>)-Pro-Pro-Gly-Phe-Ser-D-Tic-Oic-Arg-OH

MS(FAB) : 1345 (M+H)

**Example 130:**

H-Lys-Arg(Tos)-Pro-Pro-Gly-Phe-Ser-D-Tic-Oic-Arg-OH

MS(FAB) : 1408 (M+H)

**Example 131:**

H-D-Arg-Lys(Nicotinoyl)-Pro-Hyp-Gly-Phe-Ser-D-Tic-Oic-Arg-OH

MS(FAB) : 1375 (M+H)

**Example 132:**

H-D-Arg-Lys(-CO-NH-C<sub>6</sub>H<sub>5</sub>)-Pro-Hyp-Gly-Phe-Ser-D-Tic-Oic-Arg-OH

MS(FAB) : 1389 (M+H)

**Example 133:**

H-D-Arg-Arg(Tos)-Pro-Hyp-Gly-Phe-Ser-D-Tic-Oic-Arg-OH

MS(FAB) : 1452 (M+H)

**Example 134:**

H-Lys-Lys(Nicotinoyl)-Pro-Hyp-Gly-Phe-Ser-D-Tic-Oic-Arg-OH  
MS(FAB) : 1347 (M+H)

**Example 135:**

H-Lys-Lys(-CO-NH-C<sub>6</sub>H<sub>5</sub>)-Pro-Hyp-Gly-Phe-Ser-D-Tic-Oic-Arg-  
OH  
MS(FAB) : 1361 (M+H)

**Example 136:**

H-Lys-Arg(Tos)-Pro-Hyp-Gly-Phe-Ser-D-Tic-Oic-Arg-OH  
MS(FAB) : 1424 (M+H)

**Example 137:**

H-D-Arg-Orn(Nicotinoyl)-Pro-Pro-Gly-Thia-Ser-D-Tic-Oic-Arg-  
OH  
MS(FAB) : 1351 (M+H)

**Example 138:**

H-D-Arg-Orn(-CO-NH-C<sub>6</sub>H<sub>5</sub>)-Pro-Pro-Gly-Thia-Ser-D-Tic-Oic-  
Arg-OH  
MS(FAB) : 1428 (M+H)

**Example 139:**

H-Lys-Orn(Nicotinoyl)-Pro-Pro-Gly-Thia-Ser-D-Tic-Oic-Arg-  
OH  
MS(FAB) : 1323 (M+H)

**Example 140:**

H-Lys-Orn(-CO-NH-C<sub>6</sub>H<sub>5</sub>)-Pro-Pro-Gly-Thia-Ser-D-Tic-Oic-Arg-OH  
MS(FAB) : 1337 (M+H)

**Example 141:**

H-D-Arg-Orn(Nicotinoyl)-Pro-Hyp-Gly-Thia-Ser-D-Tic-Oic-Arg-  
OH  
MS(FAB) : 1367 (M+H)

Example 142:

H-D-Arg-Orn(-CO-NH-C<sub>6</sub>H<sub>5</sub>)-Pro-Hyp-Gly-Thia-Ser-D-Tic-Oic-Arg-OH

MS(FAB) : 1381 (M+H)

Example 143:

H-Lys-Orn(Nicotinoyl)-Pro-Hyp-Gly-Thia-Ser-D-Tic-Oic-Arg-OH

MS(FAB) : 1339 (M+H)

Example 144:

H-Lys-Orn(-CO-NH-C<sub>6</sub>H<sub>5</sub>)-Pro-Hyp-Gly-Thia-Ser-D-Tic-Oic-Arg-OH

MS(FAB) : 1353 (M+H)

Example 145:

H-D-Arg-Orn(Nicotinoyl)-Pro-Pro-Gly-Phe-Ser-D-Tic-Oic-Arg-OH

MS(FAB) : 1345 (M+H)

5

Example 146:

H-D-Arg-Orn(-CO-NH-C<sub>6</sub>H<sub>5</sub>)-Pro-Pro-Gly-Phe-Ser-D-Tic-Oic-Arg-OH

MS(FAB) : 1359 (M+H)

Example 147:

H-Lys-Orn(Nicotinoyl)-Pro-Pro-Gly-Phe-Ser-D-Tic-Oic-Arg-OH

MS(FAB) : 1317 (M+H)

Example 148:

H-Lys-Orn(-CO-NH-C<sub>6</sub>H<sub>5</sub>)-Pro-Pro-Gly-Phe-Ser-D-Tic-Oic-Arg-OH

MS(FAB) : 1331 (M+H)

Example 149:

H-D-Arg-Orn(Nicotinoyl)-Pro-Hyp-Gly-Phe-Ser-D-Tic-Oic-Arg-OH

MS(FAB) : 1361 (M+H)



**Example 150:**

H-D-Arg-Orn(CO-NH-C<sub>6</sub>H<sub>5</sub>)-Pro-Hyp-Gly-Phe-Ser-D-Tic-Oic-Arg-OH

MS(FAB) : 1375 (M+H)

**Example 151:**

H-Lys-Orn(Nicotinoyl)-Pro-Hyp-Gly-Phe-Ser-D-Tic-Oic-Arg-OH

MS(FAB) : 1333 (M+H)

**Example 152:**

H-Lys-Orn(-CO-NH-C<sub>6</sub>H<sub>5</sub>)-Pro-Hyp-Gly-Phe-Ser-D-Tic-Oic-Arg-OH

MS(FAB) : 1347 (M+H)

**Example 153:**

H-Lys-Lys-Pro-Pro-Gly-Thia-Ser-(D)-Tic-Aoc-Arg-OH

MS(FAB) : 1218 (M+H)

**Example 154:**

H-Lys-Lys-Pro-Hyp-Gly-Thia-Ser-(D)-Tic-Aoc-Arg-OH

MS(FAB) : 1234 (M+H)

**Example 155:**

H-Lys-Lys-Hyp-Pro-Gly-Thia-Ser-(D)-Tic-Aoc-Arg-OH

MS(FAB) : 1234 (M+H)

**Example 156:**

H-Lys-Lys-Pro-Pro-Gly-Phe-Ser-(D)-Tic-Aoc-Arg-OH

MS(FAB) : 1212 (M+H)

**Example 157:**

H-Lys-Lys-Pro-Hyp-Gly-Phe-Ser-(D)-Tic-Aoc-Arg-OH

MS(FAB) : 1228 (M+H)

**Example 158:**

H-Lys-Lys-Pro-Pro-Gly-Thia-Ser-(D)-Tic-Oic-Arg-OH

MS(FAB) : 1232 (M+H)

**Example 159:**

H-Lys-Lys-Pro-Hyp-Gly-Thia-Ser-(D)-Tic-Oic-Arg-OH  
MS(FAB) : 1248 (M+H)


**Example 160:**

H-Lys-Lys-Hyp-Pro-Gly-Thia-Ser-(D)-Tic-Oic-Arg-OH  
MS(FAB) : 1226 (M+H)

**Example 161:**

H-Lys-Lys-Pro-Hyp-Gly-Phe-Ser-(D)-Tic-Oic-Arg-OH  
MS(FAB) : 1242 (M+H)

The Examples 162-164 were prepared analogously to Example 32 using the resin having the structure



described in EP-A 322,348.

**Example 162:**

H-D-Arg-Arg-Pro-Hyp-Gly-Phe-Ser-D-Tic-Aoc-Arg-NH<sub>2</sub>  
MS(FAB) : 1283 (M+H)

**Example 163:**

H-D-Arg-Arg-Hyp-Pro-Gly-Phe-Ser-D-Tic-Aoc-Arg-NH<sub>2</sub>  
MS(FAB): 1283 (M+H)

**Example 164:**


**H-D-Arg-Arg-Pro-Pro-Gly-Phe-Ser-D-Tic-Aoc-Arg-NH<sub>2</sub>**

**MS(FAB): 1267 (M+H)**

~~XXXXXXXXXXXX~~

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A peptide of the formula I



in which

A a<sub>1</sub>) denotes hydrogen,

(C<sub>1</sub>-C<sub>8</sub>)-alkyl,

(C<sub>1</sub>-C<sub>8</sub>)-alkanoyl,

(C<sub>1</sub>-C<sub>8</sub>)-alkoxycarbonyl or

(C<sub>1</sub>-C<sub>8</sub>)-alkylsulfonyl,

in which in each case 1, 2 or 3 hydrogen atoms are optionally replaced by 1, 2 or 3 identical or different radicals from the series comprising

carboxyl,

amino,

(C<sub>1</sub>-C<sub>4</sub>)-alkyl,

(C<sub>1</sub>-C<sub>4</sub>)-alkylamino,

hydroxyl,

(C<sub>1</sub>-C<sub>4</sub>)-alkoxy,

halogen,

di-(C<sub>1</sub>-C<sub>4</sub>)-alkylamino,

carbamoyl,

sulfamoyl,

(C<sub>1</sub>-C<sub>4</sub>)-alkoxycarbonyl,

(C<sub>6</sub>-C<sub>12</sub>)-aryl and

(C<sub>6</sub>-C<sub>12</sub>)-aryl-(C<sub>1</sub>-C<sub>3</sub>)-alkyl, or in which in each case 1 hydrogen atom is optionally replaced by a radical from the series comprising

(C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl,

(C<sub>1</sub>-C<sub>4</sub>)-alkylsulfonyl,

(C<sub>1</sub>-C<sub>4</sub>)-alkylsulfinyl,

(C<sub>6</sub>-C<sub>12</sub>)-aryl-(C<sub>1</sub>-C<sub>4</sub>)-alkylsulfonyl,

(C<sub>6</sub>-C<sub>12</sub>)-aryl-(C<sub>1</sub>-C<sub>4</sub>)-alkylsulfinyl,

(C<sub>6</sub>-C<sub>12</sub>)-aryloxy,

(C<sub>3</sub>-C<sub>8</sub>)-heteroaryl and

(C<sub>3</sub>-C<sub>8</sub>)-heteroaryloxy

and

1 or 2 hydrogen atoms are replaced by 1 or 2 identical or different radicals from the series comprising

carboxyl,  
amino,  
(C<sub>1</sub>-C<sub>4</sub>)-alkylamino,  
hydroxyl,  
(C<sub>1</sub>-C<sub>4</sub>)-alkoxy,  
halogen,  
di-(C<sub>1</sub>-C<sub>4</sub>)-alkylamino,  
carbamoyl,  
sulfamoyl,  
(C<sub>1</sub>-C<sub>4</sub>)-alkoxycarbonyl,  
(C<sub>6</sub>-C<sub>12</sub>)-aryl and  
(C<sub>6</sub>-C<sub>12</sub>)-aryl-(C<sub>1</sub>-C<sub>3</sub>)-alkyl,

a<sub>2</sub>) denotes (C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl,  
carbamoyl, which may be optionally substituted on  
the nitrogen by (C<sub>1</sub>-C<sub>6</sub>)-alkyl or (C<sub>6</sub>-C<sub>12</sub>)-aryl,  
(C<sub>6</sub>-C<sub>12</sub>)-aryl,  
(C<sub>7</sub>-C<sub>18</sub>)-aryloyl,  
(C<sub>6</sub>-C<sub>12</sub>)-arylsulfonyl or  
(C<sub>3</sub>-C<sub>9</sub>)-heteroaryl or (C<sub>3</sub>-C<sub>9</sub>)-heteroaryloyl,

where in the radicals defined under a<sub>1</sub>) and a<sub>2</sub>) in each case heteroaryl, aryloyl, arylsulfonyl and heteroaryloyl is optionally substituted by 1, 2, 3 or 4 identical or different radicals from the series comprising

carboxyl,  
amino,  
nitro,  
(C<sub>1</sub>-C<sub>4</sub>)-alkylamino,  
hydroxyl,  
(C<sub>1</sub>-C<sub>4</sub>)-alkyl,  
(C<sub>1</sub>-C<sub>4</sub>)-alkoxy,  
halogen,  
cyano,  
di-(C<sub>1</sub>-C<sub>4</sub>)-alkylamino,  
carbamoyl,  
sulfamoyl and  
(C<sub>1</sub>-C<sub>4</sub>)-alkoxycarbonyl, or

a<sub>2</sub>) denotes a radical of the formula II





R<sup>1</sup> is defined as A under a<sub>1</sub>) or a<sub>2</sub>),  
 R<sup>2</sup> denotes hydrogen or methyl,  
 R<sup>3</sup> denotes hydrogen or  
 (C<sub>1</sub>-C<sub>6</sub>)-alkyl, preferably (C<sub>1</sub>-C<sub>4</sub>)-alkyl,  
 which is optionally monosubstituted by  
 amino,  
 substituted amino,  
 hydroxyl,  
 carboxyl,  
 carbamoyl,  
 guanidino,  
 substituted guanidino,  
 ureido,  
 mercapto,  
 methylmercapto,  
 phenyl,  
 4-chlorophenyl,  
 4-fluorophenyl,  
 4-nitrophenyl,  
 4-methoxyphenyl,  
 4-hydroxyphenyl,  
 phthalimido,  
 4-imidazolyl,  
 3-indolyl,  
 2-thienyl,  
 3-thienyl,  
 2-pyridyl,  
 3-pyridyl or  
 cyclohexyl,

where substituted amino stands for a compound -NH-A- and  
 substituted guanidino stands for a compound  
 -NH-C(NH)-NH-A, in which A is defined as under a<sub>1</sub>) or a<sub>2</sub>);

B stands for a basic amino acid in the L- or D-con-  
 figuration, which may be substituted in the side  
 chain;

C stands for a compound of the formula IIIa or IIIb



in which

G' independently of one another denotes a radical of the formula IV



in which

R<sup>4</sup> and R<sup>5</sup> together with the atoms carrying them form a heterocyclic mono-, bi- or tricyclic ring system having 2 to 15 carbon atoms, and

n is 2 to 8;

E stands for the radical of an aromatic amino acid;

F independently of one another denotes the radical of a neutral, acidic or basic, aliphatic or aromatic amino acid which may be substituted in the side chain, or stands for a direct bond;

(D)-Tic denotes the radical of the formula V



G is as defined above for G' or denotes a direct bond;

F' is as defined for F, denotes a radical -NH-(CH<sub>2</sub>)<sub>n</sub>-, with n = 2 to 8, or, if G does not denote a direct bond, can stand for a direct bond, and

I is -OH, -NH<sub>2</sub> or -NHC<sub>2</sub>H<sub>5</sub>,

K denotes the radical -NH-(CH<sub>2</sub>)<sub>x</sub>-CO- with x = 1-4 or stands for a direct bond, and

M is as defined for F, and their physiologically tolerable salts.

2. A peptide of the formula I as claimed in claim 1, in which

B denotes Arg, Lys, Orn, 2,4-diaminobutyroyl or an L-homoarginine radical, where in each case the amino or guanidino group of the side chain may be sub-

stituted by A as described under  $a_1$ ) or  $a_2$ ) in claim 1;

E stands for the radical of an aromatic amino acid in the L- or D-configuration, which contains 6 to 14 carbon atoms in the aryl moiety as ring members, such as phenylalanine which is optionally substituted by halogen in the 2-, 3- or 4-position, tyrosine, O-methyltyrosine, 2-thienylalanine, 2-pyridylalanine or naphthylalanine;

F' denotes the radical of a basic amino acid in the L- or D-configuration, such as Arg or Lys, where the guanidino group or amino group of the side chain may be replaced by A as described under  $a_1$ ) or  $a_2$ ) in claim 1, or denotes a radical  $-NH-(CH_2)_n-$  with  $n = 2$  to 8 and

K stands for the radical  $-NH-(CH_2)_x-CO-$  with  $x = 2-4$  or denotes a direct bond.

3. A peptide of the formula I as claimed in claim 1 and/or 2 in which

B denotes Arg, Orn or Lys, where the guanidino group or the amino group of the side chain is unsubstituted or may be substituted by  $(C_1-C_8)$ -alkanoyl,  $(C_7-C_{13})$ -aryloyl,  $(C_3-C_9)$ -heteroaryloyl,  $(C_1-C_8)$ -alkylsulfonyl or  $(C_6-C_{12})$ -arylsulfonyl, where the aryl, heteroaryl, aryloyl, arylsulfonyl and heteroaryloyl radicals may optionally be substituted, as described under  $a_2$ ), with 1, 2, 3 or 4 identical or different radicals.

E denotes phenylalanine, 2-chlorophenylalanine, 3-chlorophenylalanine, 4-chlorophenylalanine, 2-fluorophenylalanine, 3-fluorophenylalanine, 4-fluorophenylalanine, tyrosine, O-methyltyrosine or  $\beta$ -(2-thienyl)alanine;



K stands for a direct bond and

M stands for a direct bond.

4. A peptide of the formula I as claimed in one or more of claims 1 to 3 in which

A denotes hydrogen, (D)- or (L)-H-Arg, (D)- or (L)-H-Lys or (D)- or (L)-H-Orn;

B denotes Arg, Orn or Lys, where the guanidino group or the amino group of the side chain may be substituted by hydrogen, (C<sub>1</sub>-C<sub>8</sub>)-alkanoyl, (C<sub>7</sub>-C<sub>13</sub>)-aryloyl, (C<sub>3</sub>-C<sub>9</sub>)-heteroaryloyl, (C<sub>1</sub>-C<sub>8</sub>)-alkylsulfonyl or (C<sub>6</sub>-C<sub>12</sub>)-arylsulfonyl, where the aryl, heteroaryl, aryloyl, arylsulfonyl and heteroaryloyl radicals may optionally be substituted with 1, 2, 3 or 4 identical or different radicals from the series comprising methyl, methoxy and halogen.

C denotes Pro-Pro-Gly, Hyp-Pro-Gly or Pro-Hyp-Gly

E denotes Phe or Thia

F denotes Ser, Hser, Lys, Leu, Val, Nle, Ile or Thr

K stands for a direct bond

M stands for a direct bond

G stands for the radical of a heterocyclic ring system of the formula IV, where the radicals of the heterocycles pyrrolidine (A); piperidine (B); tetrahydroisoquinoline (C); cis- and trans-decahydroisoquinoline (D); cis-endo-octahydroindole (E), cis-exo-octahydroindole (E), trans-octahydroindole (E), cis-endo-, cis-exo-, trans-octahydrocyclopentano[b]pyrrole, (F) or hydroxyproline (V) are preferred.

F' denote Arg and  
I stands for OH.

5. The preparation of a peptide of the formula I as claimed in one or more of claims 1 to 4, which comprises
  - a) reacting a fragment having a C-terminal free carboxyl group or its activated derivative with an appropriate fragment having an N-terminal free amino group or
  - b) synthesizing the peptide stepwise, optionally splitting off one or more protective groups temporarily introduced for the protection of other functions in the compound obtained according to (a) or (b) and optionally converting the compounds of the formula I thus obtained into their physiologically tolerable salt.
6. Use of a peptide of the formula I as claimed in one or more of claims 1 to 4 as a medicament.
7. Use of a peptide of the formula I as claimed in one or more of claims 1 to 4 for the treatment of pathological states which are mediated, caused or supported by bradykinin and bradykinin-related peptides.
8. A pharmaceutical agent containing a peptide of the formula I as claimed in one or more of claims 1 to 4.

DATED this 8th day of August 1989.

HOECHST AKTIENGESELLSCHAFT

WATERMARK PATENT & TRADEMARK ATTORNEYS  
50 QUEEN STREET  
MELBOURNE. VIC. 3000.